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Chapter I 
 
 
INTRODUCTION 
 
The prevalence of obesity is increasing and it is projected to get worse with 
approximately 50% of the US population becoming obese by the year 2030. Obesity is a primary 
risk factor for Type 2 diabetes (T2D). As body mass increases so does the risk of developing 
T2D. Consequently, the number of individuals with T2D has risen to epidemic proportions. It is 
estimated that approximately 9.3% of the United States population had T2D in 2012 with an 
estimated 1.7 million new diagnoses occurring every year (http://www.diabetes.org/diabetes-
basics/statistics).  
Insulin resistance precedes the development of T2D (1,2). In healthy individuals, insulin 
secreted by the β-cells of the pancreas facilitates glucose homeostasis by suppressing hepatic 
glucose production and increasing glucose disposal by peripheral tissues. In the insulin resistant 
state, the skeletal muscle and liver are no longer able to respond to insulin. This results in an 
elevation of blood glucose due in part to impaired peripheral glucose uptake and increased 
hepatic glucose production despite high levels of circulating insulin. The insulin resistant state is 
characterized by hyperglycemia. However T2D does not occur until the β-cells of the pancreas 
fail to produce sufficient insulin. The liver is integral to maintaining whole-body glucose 
homeostasis; therefore understanding the mechanisms underlying hepatic adaptations to obesity 
are critical to developing potential therapeutic targets and treating T2D. 
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The liver is essential for whole-body glucose homeostasis 
The liver is central for maintaining glucose homeostasis. This is achieved through its 
ability to regulate glucose output, uptake and storage depending on the metabolic state of the 
body. The liver is a major insulin-responsive organ. In the presence of insulin, hepatic glucose 
disposal is enhanced and hepatic glucose production (also termed endogenous glucose 
production or EGP) is suppressed (1,3,4). Both processes greatly contribute to whole-body 
glucose homeostasis. The contribution of insulin-mediated suppression of hepatic glucose 
production to the regulation of glucose homeostasis was originally demonstrated in a study by 
Basu et al. (5). In this study, EGP was determined in nondiabetic and T2D subjects in the 
postprandial state. Blood glucose was clamped at postprandial levels (~8mmol/l) and insulin was 
infused at different physiological doses. EGP was higher in individuals with T2D compared to 
nondiabetic individuals despite the same experimental glucose and insulin concentrations. This 
original study was subsequently expanded into another study that included individuals with both 
“mild” diabetes (fasting glucose ~8mmol/l) and “severe” diabetes (fasting glucose ~12mmol/l) 
(6). In this study, hyperinsulinemic-euglycemic (insulin) clamps were performed and EGP was 
measured in the fasted state and during the insulin clamp. As previously reported, EGP was 
increased in the fasted state in patients with severe diabetes. However, there was no difference in 
fasting EGP between mild diabetic and nondiabetic individuals. The lack of differences in fasting 
endogenous glucose production between individuals with mild diabetes and nondiabetic 
individuals was attributed to higher fasting insulin levels in individuals with mild diabetes. Most 
importantly, EGP during the insulin clamp was higher in individuals with mild and severe 
diabetes compared to nondiabetic individuals. Collectively, these studies demonstrate that 
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abnormal regulation of hepatic glucose metabolism occurs early in the development of T2D and 
individuals with T2D have hepatic insulin resistance.  
 
Mechanisms of hepatic insulin action  
Defects in hepatic insulin signaling can lead to insulin resistance and eventually T2D 
(1,2). In nondiabetic individuals, dietary glucose stimulates insulin secretion from pancreatic β-
cells. Insulin then travels directly to the liver through the portal vein. The liver is a major site of 
insulin clearance. It is estimated that 50% of insulin is extracted by the liver during the first pass 
via a receptor-mediated process (7-9). The majority of liver insulin uptake is attributed to 
hepatocytes and a small portion, approximately 15%, is due to Kupffer cells (8). 
The uptake of insulin into the liver can vary depending on several physiological or 
pathophysiological factors including nutrient status, obesity and hyperinsulinemia. Insulin 
clearance rates by the liver are decreased in obesity and glucose intolerance (10). Moreover, 
hepatic insulin extraction is decreased in the ob/ob mouse model (11). This is attributed to 
hyperinsulinemia and the subsequent downregulation of hepatic insulin receptors. Hence, the 
ability of the liver to extract insulin from the circulation may impact its ability to properly 
respond to an insulin stimulus.  
Insulin exerts its biological effects through the insulin receptor (12). The insulin receptor 
is a tetrameric protein that consists of two extracellular α subunits and two transmembrane β 
subunits bound by disulfide bonds. Once insulin reaches the hepatocyte and binds its receptor, a 
conformational change occurs resulting in the activation and subsequent tyrosine kinase 
autophosphorylation of the β subunits. This leads to the recruitment of receptor substrates such 
as insulin receptor substrate (IRS) proteins. IRS proteins are recruited to the membrane and 
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activated receptors where they are subsequently phosphorylated on multiple tyrosine residues 
(13). Along with the IRS proteins, the insulin receptor can phosphorylate other substrates such as 
Shc proteins involved in the activation of the Ras/ERK signaling cascade (14).  
Both IRS1 and IRS2 are critical for activation of the PI3-kinase-Akt signaling cascade. 
Akt can be phosphorylated at 2 sites by its activating kinases that are important for insulin 
signaling, Ser473 and Thr308. There are three described isoforms of Akt encoded by different 
genes: Akt1, Akt2 and Akt3 (15). In mouse liver, Akt2 is the predominant isoform which 
constitutes approximately 84% of all Akt protein. The remaining Akt protein consists entirely of 
Akt1 as Akt3 cannot be detected. Upon Akt activation, it phosphorylates and either activates or 
inactivates several downstream proteins to modulate distinct metabolic pathways. One pathway 
modulates protein synthesis and cell growth through the inactivation of tuberous sclerosis (TSC) 
1-2 complex. Another pathway facilitates glycogen storage through the inactivation of glycogen 
synthase kinase (GSK)-3β. A third pathway, and the most important for insulin action in the 
liver, facilitates the phosphorylation and nuclear exclusion of a key modulator of gluconeogenic 
gene expression, forkhead box O1 (Foxo1) (16). Akt phosphorylates Foxo1 at several sites 
including Ser253, Ser316 and Thr24. This provides docking sites for proteins of the 14-3-3 
family and blocks the entry of Foxo1 into the nucleus. The nuclear exclusion of Foxo1 prohibits 
gene expression of the gluconeogenic genes glucose 6-phosphatase (G6pase) and 
phosphoenolpyruvate carboxykinase (Pepck) resulting in a decrease in hepatic glucose 
production.    
In the insulin resistant state, insulin fails to produce its desired biological effect due to 
defects in insulin receptor autophosphorylation and/or decreased activation of its downstream 
effectors (17). This results in the hallmark of hepatic insulin resistance which is increased 
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hepatic glucose production despite an insulin stimulus. Multiple mechanisms have been 
described for the downregulation of insulin signaling within the hepatocyte (Figure 1.1). These 
include decreased phosphorylation of the insulin receptor and/or IRS proteins, suppressor of 
cytokine signaling (SOCS) protein upregulation/activation, phosphatases, and inhibitory serine 
phosphorylation of IRS proteins as well as the insulin receptor (18). Much of this has been 
established through the use of genetic manipulations in mouse models. Liver-specific insulin 
receptor knockout (LIRKO) mice and liver-specific IRS1 and IRS2 double knockout (DKO) 
mice develop hyperinsulinemia, glucose intolerance and severe insulin resistance associated with 
impaired insulin signaling (19,20).  
Most interestingly, of all the proposed regulators of hepatic insulin action, it appears that 
Foxo1 regulation by Akt is particularly important for the suppression of insulin-mediated hepatic 
glucose production. In the insulin resistant liver, Foxo1 translocates to the nucleus where it 
promotes the transcriptional upregulation of G6Pase and PEPCK. Transgenic mice expressing a 
Foxo1 dominant negative mutant (Foxo1-∆256) exhibit a significant reduction in hepatic G6pase 
and Pepck mRNA (21). Both G6Pase and PEPCK are regulated at the transcriptional level and 
are not subject to post-translational modifications (22). PEPCK catalyzes the conversion of 
oxaloacetate to phosphoenolpyruvate. Phosphoenolpyruvate is then converted into glucose 
through several enzyme-mediated reactions. The PEPCK reaction is a rate limiting step for 
gluconeogenesis. In contrast, G6Pase catalyzes the hydrolysis of glucose-6-phosphate to glucose. 
The glucose is then transported across the ER and plasma membranes through the glucose T2 
and GLUT2 transporters where it is then released into the circulation.  
The contribution of Foxo1 to hepatic glucose production in the insulin resistant state was 
addressed in a study by Lu et al. (23). In this study, mice with a hepatic deletion of Akt1, Akt2 
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Figure 1.1 – Intracellular mechanisms of hepatic insulin resistance. In the insulin resistant state, 
there are multiple mechanisms that exist for down regulating insulin signaling such as SOCS 
proteins, phosphatases and inhibitory serine phosphorylation of IRS proteins and the insulin 
receptor. This results in decreased hepatic insulin signaling and the hallmarks of hepatic insulin 
resistance including increased hepatic glucose production and lipid production. 
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and both Akt and Foxo1 were studied to determine their relative contributions to the suppression 
of hepatic glucose production in the presence of insulin. The mice with a hepatic deletion of 
Akt1 and Akt2 were insulin resistant. Strikingly, the insulin resistance was normalized and 
hepatic glucose production was suppressed when Foxo1 was also deleted. This indicates that 
hepatic Akt plays a major role in preventing the activation of Foxo1 and when Foxo1 is absent, 
Akt is not necessary for the suppression of hepatic glucose production.  
The termination of insulin action occurs upon the internalization and degradation of 
insulin-receptor complexes (24). This process happens within minutes of receptor binding. 
Studies in either isolated hepatocytes (25) or perfused livers (26) have shown that insulin is 
initially localized to the plasma membrane and by 10 min, over half of the insulin is internalized. 
Receptor-bound insulin can also be released from the cell where it re-enters the circulation (27).  
 
Mechanisms of hepatic lipid accumulation and nonalcoholic fatty liver disease (NAFLD) 
Insulin promotes hepatic triglyceride (TG) synthesis and storage within the liver. In times 
of excess caloric intake, a disproportionate amount of hepatic fat accumulation occurs within the 
liver. When more than 5-10% of the liver’s weight consists of fat, then it is referred to as a fatty 
liver. This is also referred to as nonalcoholic fatty liver disease (NAFLD). NAFLD is the leading 
cause of liver dysfunction in the US (28). It is estimated that approximately 25% of the US 
population has NAFLD (http://www.liverfoundation.org/abouttheliver/info/nafld/).   
There are several metabolic pathways that contribute to increased hepatic lipid 
accumulation in the presence of over nutrition (Figure 1.2). These include: increased fat delivery, 
increased fat synthesis, reduced fat export, and decreased cellular utilization of fats (28-30). High 
circulating levels of serum free fatty acids (FFA) are positively correlated with NAFLD (31).  
8 
 
 
 
Figure 1.2 – Metabolic pathways leading to hepatic triglyceride accumulation. There are several 
metabolic pathways that lead to hepatic TG accumulation. Under conditions of insulin resistance, 
lipolysis in white adipose tissue is not suppressed. This leads to increased FFA flux into the 
circulation. In addition, hyperglycemia and hyperinsuinemia promote lipogenesis and 
mitochondrial oxidation is impaired. After the esterification step TGs can then be stored as lipid 
droplets within hepatocytes or secreted into the blood as VLDL. 
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Increased circulating FFAs can occur due to increased lipolysis (the hydrolysis of TGs) or 
increased dietary intake of fat. Under normal conditions, insulin suppresses lipolysis in the 
adipose tissue. In insulin resistant human patients with NAFLD, insulin fails to suppress lipolysis 
in white adipose tissue to the same extent as healthy patients (32). This results in increased FFA 
release from the adipose tissue and a subsequent higher rate of entry into the circulation due in 
part to the failure of insulin to adequately inhibit hormone sensitive lipase (HSL) (33). Studies in 
HSL-null mice exhibit decreased circulating FFAs and a concomitant decrease in liver TG levels 
(34).  
FFAs are taken up from the circulation by fatty acid transporters located on the cell 
surface of the hepatocyte such as CD36/FAT. CD36 is a transmembrane protein that promotes 
fatty acid uptake via facilitated diffusion. CD36 is an important regulator of fatty acid uptake 
into the hepatocyte and its expression is positively correlated with liver fat in patients with 
NAFLD (35). In the basal state, the expression of CD36 on hepatocytes is low; however its 
expression increases significantly with HF feeding (36). Mice fed a HF diet (60%) for 5 weeks 
displayed a 2.6-fold increase in CD36 protein expression. This correlated with a 1.7-fold increase 
in hepatic TG content suggesting that increased CD36 expression correlates with increased TG 
accumulation in mice fed a HF diet. Moreover, overexpression of CD36 via adenovirus resulted 
in an increase in hepatic fatty acid uptake and TG storage. These data suggest that CD36 
expression regulates fatty acid uptake into the liver and a rise in CD36 expression that occurs 
with HF feeding is associated with increased hepatic TG accumulation. Once FFAs enter into the 
liver, they can be esterified into TGs where they can be stored as lipid droplets within 
hepatocytes.  
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Increased fat delivery via high levels of circulating FFAs is a major determinant of 
hepatic TG accumulation (30,37). The relative contribution of FFAs to liver TGs in human 
patients with NAFLD was determined in a study by Donnelly et al. (30). In this study, a multiple 
stable isotope approach was used to estimate the relative contributions of circulating FFAs, de 
novo lipogenesis and the diet to liver fat accumulation. Their results showed that approximately 
59% was due to FFAs, 26% arose from de novo lipogenesis and the remaining 15% was from the 
diet. This suggests that although there are many pathways that can lead to TG accumulation in 
the liver, elevated circulating FFAs are the largest contributor to the development of NAFLD.   
As stated above, increased de novo lipogenesis (DNL) is the second largest contributor of 
hepatic TG accumulation in humans with NAFLD (30). DNL is an integrated metabolic pathway 
comprised of glycolysis (conversion of glucose to acetyl-CoA), synthesis of saturated fatty acid 
followed by desaturation, and the formation of TGs (28). There are several key enzymes that 
regulate DNL. These include acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), long 
chain fatty acid elongase 6 (ELOVL6), stearoyl-CoA desaturase (SCD), glycerol-3-phosphate 
acyltransferase (GPAT) and diacylglycerol acyltransferase (DGAT). ACC and FAS are involved 
in fatty acid synthesis. ELOVL6 and SCD facilitate the formation of monounsaturated fatty 
acids. GPAT and DGAT regulate the formation of TGs.     
The enzymes responsible for DNL are transcriptionally regulated by both carbohydrate 
responsive element-binding protein (ChREBP) and sterol regulatory element-binding protein-1c 
(SREBP-1c). These pathways are regulated by nutritional status and synergistically respond to 
glucose and carbohydrate, respectively. Glucose activates ChREBP by regulating its entry into 
the nucleus from the cytosol where it regulates the transcription of its target genes as part of a 
heterodimeric complex with Mlx (Max-like protein X) (38,39). In contrast, SREBP-1c is 
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transcriptionally regulated by insulin and it regulates gene expression through its ability to bind 
sterol regulatory elements (SREs) within the promoter of its target genes (40). This is evidenced 
by a rise in SREBP-1c gene and protein expression when insulin levels are high, such as during 
refeeding with a high carbohydrate diet (41). Collectively, ChREBP and SREBP-1c regulate the 
transcription of enzymes involved in fatty acid synthesis such as ACC, FAS, ELOVL6, and 
SCD1 as well as enzymes involved in TG synthesis such as GPAT.   
Genetic manipulations in mice have added a great amount to the understanding of the 
regulation of lipogenic gene expression in response to glucose and/or insulin. ChREBP-1c 
overexpressing mice on either a chow and HF diet exhibit increased liver fat accumulation and 
increased expression of genes involved in lipogenesis such as Acc, Elovl6 and Scd1 compared to 
controls (42). Transgenic mice that overexpress SREBP-1c in the liver display increased 
lipogenic gene expression and increased lipid accumulation (43). Additionally, the synergistic 
regulation of lipogenic gene expression by both ChREBP and SREBP-1c was established in a 
study using mice with a genetic deletion of SREBP-1c (44). In this study, the deletion of 
SREBP-1c resulted in only a 50% reduction in hepatic gene expression of Acc and Fas. When 
these mice were fasted and refed, thus generating an insulin response, it was observed that there 
was no induction of gene expression of Gpat. This suggests that SREBP-1c is only partially 
responsible for gene expression of Acc and Fas, while it may be completely responsible for the 
transcriptional regulation of Gpat. It is also interesting to note that the SREBP-1c null mice 
exhibit a marked decrease in hepatic TG accumulation compared to the wild-type control mice in 
response to a high carbohydrate meal.   
Mitochondria are metabolically flexible organelles that can adapt to increased fatty acid 
oxidation to a limited extent when provided with excess substrate (45). Mitochondrial β-
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oxidation of fatty acids serves to shorten the fatty acids into acetyl-CoA where they are either 
converted into ketone bodies (β-hydroxybutyrate) or enter the TCA cycle. The NADH and 
FADH2 produced by both β-oxidation and the TCA cycle are used as substrates for oxidative 
phosphorylation. When the supply of FFAs exceeds the amount the mitochondria can oxidize, 
hepatic fat accumulation occurs. In light of this, mitochondrial dysfunction is associated with the 
development of NAFLD. Mice with a heterozygous deletion of mitochondrial trifunctional 
protein (MTP) developed hepatic steatosis (46). Adiponectin knock out mice exhibit 
mitochondrial dysfunction and increased hepatic TG accumulation (47). Additionally, 
genetically obese rats display impaired mitochondrial function, decreased mitochondrial content 
and heightened liver TG content (48). Together these studies highlight the role of mitochondrial 
oxidation in the regulation of liver TG levels.       
Fat export or secretion of TGs from the liver is also a key regulatory point for the 
determination of hepatic lipid accumulation in the presence of a HF diet. TGs are secreted from 
the liver in the form of very low density lipoproteins (VLDL). VLDL consists of a hydrophobic 
core containing TGs and cholesterol esters covered by hydrophilic phospholipids and 
apolipoprotein B (apoB). It is initially assembled in the rough endoplasmic reticulum and is 
transported into the Golgi before release from the liver through exocytosis. The ability of the 
liver to export TGs through VLDL is important for reducing hepatic lipid accumulation. Human 
patients with mutations in apoB that result in dysfunctional VLDL transport have elevated 
hepatic fat accumulation (49). It is also important to note that in the insulin resistant state, VLDL 
secretion from the liver is elevated. This results in hypertriglyceridemia in humans but not in 
mice. However, increased TG secretion is unable to mitigate the upregulation of TG synthesis 
and this ultimately results in hepatic TG accumulation (50). 
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A strong correlation exists between HF feeding, increased hepatic TG accumulation and 
insulin resistance (29,51,52). Rats fed a HF diet for three days developed hepatic insulin 
resistance in the absence of an observable impairment in peripheral insulin sensitivity (53). A 
study later conducted by Samuel et al. set forth to use a similar feeding paradigm and reported a 
similar finding (51). In this study, rats were fed either a chow or HF diet (59% fat) for three days. 
Three days of HF feeding nearly tripled hepatic TG and fatty acyl-CoA content. The rats fed a 
HF diet developed hepatic insulin resistance as evidenced by increased hepatic glucose 
production during an insulin clamp. This finding was associated with diminished insulin-
stimulated Akt2 and IRS-1 and IRS-2 associated PI3-kinase activation/activity in the HF-fed 
rats. Moreover, rodent models designed to modulate fat uptake into the liver also support this 
correlation (54). The hepatic overexpression of lipoprotein lipase, which causes increased fatty 
acid uptake into the liver, results in hepatic insulin resistance and liver fat accumulation. The 
antisense oligonucleotide knockdown of the lipogenic genes ACC1 and ACC2 reduces hepatic 
lipid accumulation and improves insulin sensitivity. As a consequence, it was proposed in these 
studies and widely accepted that an increase in hepatic TGs leads to the development of hepatic 
insulin resistance.  
Despite the correlation between hepatic TG accumulation and insulin resistance, a causal 
relationship has recently become a point of contention in the literature. This is the direct result of 
several studies that show that insulin resistance can exist in the absence of increased hepatic lipid 
accumulation (28,55-58). For example, transgenic mice overexpressing DGAT2 in the liver (Liv-
dgat2 mice) exhibit full suppression of endogenous glucose production during an insulin clamp 
despite significant hepatic steatosis (56). Overexpression of hepatic ChREBP in HF-fed mice 
display increased hepatic steatosis as well as improved insulin signaling and glucose tolerance 
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compared to wild-type controls (42). ELOVL6-null mice are protected against hepatic insulin 
resistance when fed a high fat/high carbohydrate diet despite increased hepatic palmitate 
concentrations (58). This has led to an alternate hypothesis whereby hepatic TGs actually protect 
the liver from lipotoxicity by incorporating potentially harmful lipid metabolites or deleterious 
fatty acids into neutral lipid droplets. Moreover, the results from these studies also suggest that 
hepatic TG accumulation and hepatic insulin resistance can occur via independent mechanisms 
and are not necessarily linked by a common mechanism.  
 
Components of the hepatic extracellular matrix are upregulated in the insulin resistant 
state 
The pathology of NAFLD ranges from fatty liver to a more progressive form of the 
disease called nonalchoholic steatohepatisis (NASH). NASH is characterized by the presence of 
hepatocellular injury (ballooning, degeneration, Mallory bodies, as well as elevated AST and 
ALT) and liver fibrosis. The prevalence of NASH is much lower than NAFLD (59). It is 
estimated that approximately 3% of the general population is affected by NASH.  Moreover, 
while NAFLD is generally asymptomatic, the consequences of NASH are much steeper as it can 
eventually lead to progressive liver damage with complications of cirrhosis, liver failure, 
hepatocellular carcinoma and liver-related death.  
The liver is a heterogeneous tissue comprised of several different cell types including 
hepatocytes, endothelial lining cells, Kupffer cells (tissue macrophages), and stellate cells 
(previously known as Ito cells). Hepatocytes are the most abundant cell type, making up 
approximately 80% of the cells in the liver (60). Liver cells are organized into microvascular 
units called sinusoids (Figure 1.3). The sinusoidal endothelium is separated from hepatocytes by  
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Figure 1.3 – Liver architecture. In the liver, blood from the portal vein and hepatic artery drain 
into the sinusoids. The sinusoids are lined by endothelial cells. The space between the 
endothelial cells and the hepatocytes is called the Space of Disse. This portion contains 
extracellular matrix proteins.  
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the space of Disse where all metabolites from the bloodstream must pass through to reach the 
hepatocytes. The surface area of hepatocytes exposed to the space of Disse is greatly enhanced 
by the presence of microvilli (61). Under normal conditions, the space of Disse is filled with 
loosely assembled, low density extracellular matrix (ECM) proteins. 
The ECM is composed of a diverse array of proteins and proteoglycans including 
collagens, laminins, fibronectin and hyaluronic acid (62). The ECM is important for the liver as 
it provides a scaffold for hepatocytes and modulates many biological processes including 
differentiation, cell migration, repair and development (63,64). Collagens are the most abundant 
protein in humans and represent approximately 5-10% of the total hepatic protein (63). They 
consist of three α polypeptide chains folded into a triple helix formation. Moreover, collagen can 
be divided into subgroups depending on their organization and/or molecular size (63). These are 
referred to as collagen types. In the normal liver, the space of Disse consists of small bundles of 
collagen type I and fibers of collagen types III, IV and V. Collagen type I is a fibril forming 
collagen that serves as a site where other collagen types, glycoproteins and proteoglycans can 
attach. Collagen type III is similar to collagen type I as it is a member of the fibrillar collagen 
family and it often colocalizes with collagen type I in the same fibril (65). Collagen type IV is 
structurally longer than the fibrillary collagens and it surrounds the perisinusoidal surface in the 
normal liver (66). It has the ability to polymerize into a network on which other ECM 
components such as laminin and heparan sulfate proteoglycan can bind and assemble (67). 
Collagen IV is generally associated with basement membranes; however hepatic sinusoids lack a 
continuous basement membrane. This allows a site of contact between the blood and 
hepatocytes. Deposits of collagen type IV can be found in the sinusoidal space of the normal 
liver (63). Additionally, collagen type V is a minor component of the hepatic ECM. It is a fibril-
17 
 
forming collagen that forms fibrils with collagen type I and is most abundant near the central 
veins and portal triad (68).  
In addition to collagens, glycoproteins are vital elements in the organization of the ECM. 
There are several different types of glycoproteins which include fibronectin and laminin. 
Fibronectin is a key component of the hepatic ECM. It consists of two polypeptide chains 
connected by disulfide bonds. Fibronectin is predominant in the hepatic ECM and is the most 
abundant ECM component in the space of Disse. In the liver, it has been detected in all 
extracellular compartments and is a central adhesion site for collagens, fibrin and heparin. 
Studies show that it is required in vitro for the assembly of a collagen matrix (69).  
Laminin is the major glycoprotein found in basement membranes. It is a large, 
noncollagenous heterotrimeric glycoprotein made up of individual α, β and γ subunits (70). 
Laminin can polymerize with collagen IV to provide a scaffold for adjacent cells. Twelve 
different heterotrimers of laminin have been identified from various combinations of five α, three 
β and three γ chains (71). The distribution of different laminin chains depends on the location 
where they are expressed. In the liver, laminin α1 is present along the sinusoids and space of 
Disse while laminin α2 is present along the blood vessels.    
The ECM is a dynamic structure that is constantly changing and remodeling during times 
of injury and repair (72). ECM remodeling or fibrosis occurs in the liver in response to chronic 
liver injury. Chronic hepatocellular injury is a common feature in both NAFLD and NASH. The 
specific process as to how this occurs is currently undefined. However, one prevailing hypothesis 
is the “two hit” hypothesis proposed by Day et al (73). The “first hit” is the accumulation of lipid 
metabolites in hepatocytes. This leads to a series of events including lipotoxicity, oxidative 
stress, and inflammation that produce a “second hit”. The “second hit” promotes tissue injury 
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and the activation of stellate cells. Under normal conditions, stellate cells are quiescent vitamin 
A rich cells (74,75). Following liver injury, stellate cells undergo an activation process that 
transforms them from quiescent cells into proliferative and fibrogenic myofibroblasts. This 
process is initiated by autocrine and paracrine stimuli including inflammatory cytokines and 
growth factors such as platelet-derived growth factor (PDGF), endothelin-1, fibroblast growth 
factors (FGF), insulin-like growth factor (IGF) I, tumor necrosis factor (TNF)-α and 
transforming growth factor (TGF)-β (74,76,77).  
TGF-β has been heavily implicated in stellate cell activation (75). Treatment of cultured 
stellate cells with TGF-β results in an increase in type I pro-collagen gene expression (78). TGF-
β is upregulated in both rodent and human models of hepatic fibrosis (79,80). Gene expression 
for TGF-β is increased in parallel with collagen type I gene expression in two models of hepatic 
fibrosis (79). Liver biopsies from human patients with liver disease and increased collagen type I 
gene expression exhibited a 120% increase in TGF-β gene expression compared to controls (80). 
Once activated, stellate cells deposit ECM proteins in the space of Disse as part of a wound 
healing response resulting in subsequent changes in the liver ECM and fibrosis (81). 
It has been widely proposed that stellate cells are the main contributor to ECM deposition 
in the liver (82). This notion was based on in vitro studies performed in cell culture (83,84) and it 
is still unknown whether this occurs in vivo. However, several cell types of cells in the liver are 
capable of ECM synthesis (63). These are hepatocytes, endothelial cells and stellate cells. 
Hepatocytes are able to synthesize collagen types I, III, and IV, laminin and fibronectin. 
Endothelial cells are able to synthesize collagen type IV and laminin and stellate cells are able to 
synthesize collagen types I, III and IV in addition to laminin. Considering that hepatocytes 
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comprise approximately 80% of the liver, it is feasible that they may also contribute a great 
amount to the hepatic ECM under pathological conditions.      
Fibrosis is characterized by both a quantitative and qualitative change in the composition 
of the ECM. During this process, there is a several-fold (~3-5) increase in ECM proteins in 
addition to a shift from low-density ECM proteins to more fibril-forming collagens such as 
collagen type I. Hepatocytes become encased in type V collagen. Fibronectin accumulation is 
also markedly increased (66). It has been proposed that fibronectin deposition may actually 
precede collagen type I deposition and as fibrosis progresses, fibronectin disappears when 
mature collagen is formed (85). Additionally, ECM proteins accrue in the abluminal space and 
the sinusoids become enclosed in a sheath of ECM proteins (61). This process is referred to as 
sinusoidal capillarization. Increased perisinusoidal deposition of laminin allows for the formation 
of a complete basement membrane and this facilitates the capillarization process (66). Type IV 
collagen and laminin have also been implicated in this process.  
Although NASH is associated with heightened levels of liver damage and fibrosis, it is 
possible that ECM remodeling in the liver occurs early on as an adaptation to over nutrition. A 
study by Wada et al. showed that wild-type C57BL/6 mice fed a 60% HF diet with high fructose 
water for 12 weeks exhibit increased hepatic collagen I α1 gene expression compared to control 
chow fed mice (86). In addition, wild-type C57BL/6 mice fed a 42% HF diet display increased 
hepatic immunohistochemical staining for α-smooth muscle actin (SMA) and collagen as well as 
increased collagen I α1 gene expression compared to controls (87).  
Moreover, studies show that ECM remodeling is associated with T2D (88,89). In one 
study, the histology of liver biopsies was assessed in obese patients with NAFLD with and 
without T2D using immunohistochemistry. Patients with T2D had increased staining for collagen 
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IV, α-SMA and a tendency towards an increase in laminin staining. In a separate study, liver 
biopsies from patients with T2D showed increased perisinusoidal fibrosis characterized by 
immunostaining for laminin in the sinusoidal spaces as well as collagen IV and αSMA in the 
space of Disse (89). It is important to note that none of the subjects in these studies had marked 
liver fibrosis or cirrhosis. Collectively, this suggests that early markers of ECM remodeling 
occur in patients with T2D prior to more advanced fibrosis and cirrhosis.  
It is evident that a diet high in fat is associated with hepatic insulin resistance and ECM 
remodeling. However, only one study to date has demonstrated a causal link between the two 
(90). A study from our laboratory showed that depletion of systemic hyaluronan via chronic tail 
vein injection of a long-acting hyaluronidase reverses HF diet induced muscle and liver insulin 
resistance (90). It is reasonable to speculate that the cellular and microcirculatory changes (i.e. 
sinusoidal capillarization) that occur with HF feeding sensitize the liver to further damage and 
may facilitate maladaptive changes in hepatic insulin action (91). Patients with cirrhosis and 
chronic hepatitis have been shown to display decreased hepatic insulin extraction compared to 
normal subjects (24). This decrease in clearance can be attributed to either liver damage or 
shunting of the portal-systemic circulation (24). A direct end result of decreased insulin 
extraction is impaired insulin action and ultimately insulin resistance. Another possibility is that 
hepatic ECM remodeling promotes changes in cell signaling through ECM receptors called 
integrins.  
 
Integrins are receptors for ECM proteins 
Integrins are transmembrane cell surface receptors (92). They facilitate communication 
between cells and the surrounding ECM. The extracellular domains of integrins constitute the 
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ligand binding domain while the cytoplasmic domain transduces intracellular signals and 
interacts with the cytoskeleton (Figure 1.4). Integrins are heterodimers comprised of non-
covalently bound α and β subunits (93). In mammals, there are 18α and 8β subunits that can form 
a total of 24 distinct integrins. Generally, the β subunits are synthesized in excess compared with 
α subunits, thus heterodimer expression is regulated by the rate limiting synthesis of the α 
subunit (94). Once synthesized, the two subunits associate intracellularly before they are 
transported to the cell surface. 
The ligand specificity of integrins depends on the combination of α and β subunits (92). 
Integrins can be divided into subgroups based on the ligands they bind. These subgroups include 
collagen receptors, laminin receptors, RGD receptors and leukocyte-specific receptors. The 
primary collagen binding receptors are integrins α1β1, α2β1, α10β1 and α11β1. Integrins α3β1, 
α6β1, α6β4 and α7β1 are the major laminin binding receptors. The RGD sequence is a major 
integrin binding sequence found in ligands such as fibronectin. The RGD receptors include 
integrins α5β1, α8β1, αIIbβ3 and the αvβ integrins. Lastly, the leukocyte-specific receptors 
consist of the β2 integrins.  
The integrin α1 subunit is the largest of the α subunits with a molecular weight around 
190-210 kDa (95). Collagen type IV is the preferred ligand of integrin α1β1, however it is able to 
bind to several other ligands including collagen type I and laminin (96-98). This was 
demonstrated in a study by Gardner et al. in which embryonic fibroblasts isolated from integrin 
α1 null mice were plated on either collagen IV, collagen I or laminin (98). The integrin α1 null 
fibroblasts were unable to spread on collagen IV. In contrast, there was a slight effect on laminin 
and little to no effect of spreading on collagen I indicating that collagen IV is a preferred ligand. 
As a result, integrin α1β1 is important for survival on collagen substrates (99). Other integrin α1  
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Figure 1.4 – Integrin structure. Integrins are receptors for extracellular matrix proteins. They are 
heterodimeric transmembrane proteins that consist of an alpha and beta subunit. The 
extracellular portion contains the ligand-binding site that binds the ECM and the cytosolic 
portion modulates cell signaling. 
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ligands include the cartilage protein matrilin-1, TCPTP, galectins 1, 3, and 8 as well as 
semaphorin 7A expressed on macrophages (100,101). 
The integrin α1 subunit is expressed in several different tissue types including vascular 
smooth muscle, kidney, brain, skin and liver (98). In the liver, it is expressed in several different 
cell types including hepatocytes, stellate cells, vascular endothelium, connective tissue stroma 
and sinusoidal lining cells (102,103). Notably, it is the only collagen binding integrin expressed 
on the hepatocyte. There are six α subunits (α1, α2, α3, α4, α5 and α6) expressed in the liver and 
they are all associated with the β1 integrin (102). Only two integrin heterodimers have been 
shown to be expressed on the hepatocyte: integrin α1β1 and α5β1. Integrin α5β1 is a fibronectin 
receptor, thus integrin α1β1 is the sole collagen binding integrin on the hepatocyte.  
The genetic whole body deletion of integrin α1 in mice exists and is viable (98). These 
mice develop normally and are visibly indistinguishable from wild-type mice. Early studies in 
the integrin α1 null mouse demonstrated that integrin α1 null mice synthesize excess dermal 
collagen in vivo (99) as a result of increased steady state levels of collagen synthesis (104). The 
apparent increase in collagen synthesis in integrin α1 null mice is attributed to decreased MAPK 
signaling (99). The activation of integrin α1β1 signaling via ligand binding activates the MAP 
kinases Erk1 and 2 through Shc. Erk1/2 activation then reduces collagen synthesis. Collectively, 
this demonstrates that integrin α1β1 is a negative regulator of collagen synthesis via its ability to 
activate the MAPK pathway. 
Various stimuli and growth factors regulate integrin α1β1 expression (98,106-108). These 
include retinoic acid (106), cytokines (107,108), and the growth factors NGF, TGF-β, PDGF and 
TNF (98). TGF-β is a particularly potent stimulus of integrin α1 expression (109). Incubation of 
mesangial cells with TGF-β for 48 hours increases mRNA and protein synthesis of the integrin 
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α1 subunit in a dose-dependent manner (109). Moreover, integrin α1β1 expression is altered 
under conditions of liver injury as well as in disease states associated with fibrosis 
(102,103,110,111). Patients with chronic hepatitis C display increased integrin α1 expression 
(110). Male Wistar rats with diet-induced liver cirrhosis exhibit increased integrin α1 expression 
on hepatocytes and sinusoidal lining cells (112). Human liver biopsy specimens from patients 
with either inflammatory or cholestatic liver disease show increased integrin α1 expression in 
hepatocytes and connective tissue stroma (102). Additionally, two weeks of ethanol feeding in 
rats leads to increased hepatocellular expression of integrin α1 (111).   Collectively, these studies 
suggest that integrin α1 is upregulated during times of ECM remodeling. 
 
Integrins transduce signals from the ECM to the intracellular space 
Integrins are capable of bidirectional signaling. Integrin activation is regulated from the 
cytosol through ‘inside-out’ signaling. Additionally, integrin binding to the ECM transduces 
signals to the cytosol through ‘outside-in’ signaling. Inside-out signaling is important for integrin 
activation (i.e. the transition from a low to high affinity state) (113). This process is primarily 
mediated by two protein families, the talins and the kindlins. During inside-out signaling, talins 
or kindlins bind to the β-integrin cytoplasmic tail. This leads to conformational changes that 
result in integrin activation (114). Talins are large (~270 kDa) cytoplasmic proteins (115). 
Several factors have been described to modulate talin binding to integrins. These include the 
lipid second messenger PIP2 and tyrosine phosphorylation by members of the Src family of 
kinases. The kindlin family of proteins consists of three members: kindlin-1, kindlin-2 and 
kindlin-3. Kindlin-1 is found primarily in epithelial cells. Kindlin-2 is ubiquitously expressed. 
While kindlin-3 is widely expressed in several different tissue types including the spleen, thymus 
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and lymph nodes, but not in the heart, brain, liver or skeletal muscle (116). Both talins and 
kindlins are able to bind to distinct regions of integrins and modulate integrin affinity and 
activation through their cooperative ability to separate integrin cytoplasmic tails.  
Integrin ligand binding facilitates the transduction of signals from the ECM to the inside 
of the cell (i.e. outside-in cell signaling) (Figure 1.5). The cytoplasmic domains of integrins are 
critical for their ability to modulate intracellular signaling. The signals generated by integrins 
regulate a variety of cellular processes including, but not limited to, motility, proliferation, 
differentiation and gene expression. Upon ligand binding, integrins cluster in the plane of the 
plasma membrane and this triggers the generation of focal adhesion complexes. Focal adhesions 
are signaling centers composed of over 150 proteins and they provide links from the ECM to the 
cytoskeleton (117). This initiates the assembly of the cytoskeleton, namely actin, and the 
activation of several diverse downstream signaling pathways.   
Integrins themselves lack kinase activity. Thus they are reliant on downstream kinases 
and scaffolding proteins for signal transduction. Integrins signal through various proteins 
including Src-family kinases, Abl, focal adhesion kinase (FAK) and integrin-linked kinase 
(ILK). FAK is a cytoplasmic tyrosine kinase found in focal adhesions. It is targeted to focal 
adhesions through a region in its C-terminal domain called the FAT region (118). FAK localizes 
with integrin receptors at sites where cells attach to the ECM (119) and is activated by antibody 
crosslinking of β1 integrins (120). It has at least five tyrosine phosphorylation sites (Tyr397, 407, 
576, 577 and 925) (121). Moreover, FAK has also been shown to bind the integrin α1 
cytoplasmic tail (122). 
FAK undergoes rapid autophosphorylation at Tyr397 upon integrin-mediated cell 
adhesion (123) and this is associated with increased catalytic activity. Tyr397 phosphorylation  
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Figure 1.5 – Integrin signaling. Upon ligand binding, integrins transduce signals across the 
plasma membrane to facilitate cell signaling. Integrin signaling can be divided into 3 portions: 
the input, signaling molecule and biochemical response. The input is the extracellular ligand it 
binds. The signaling molecule can be very diverse and integrins can signal to many different 
molecules including ILK and FAK. These can then signal to some well-known insulin signaling 
molecules including Akt, ERK and JNK. Finally, one example of the biochemical response is 
gene expression. 
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promotes the recruitment of Src-family tyrosine kinases to focal adhesions. In turn, Src further 
promotes FAK phosphorylation at Tyr407, 576 and 577 and this leads to the recruitment of Src 
and phosphatidyl inositol 3-kinase (PI3K) as well as other proteins. Additionally, FAK has been 
shown to be regulated by the growth factor receptors EGFR, FGFR and the insulin receptor 
(124,125). This results in the activation of several downstream signaling cascades including the 
MAPK and PI3K signaling pathways (124,125). In addition to its signaling properties, FAK is 
important for cytoskeletal stabilization and focal adhesion turnover (126). 
ILK is a highly conserved intracellular scaffolding protein. It interacts with the β1, β2 
and β3-integrin cytoplasmic domains and numerous cytoskeleton-associated proteins. It is 
composed of three distinct domains: an N-terminus that contains five ankyrin repeats, a 
pleckstrin homology-like domain and a pseudokinase domain at the C-terminus. ILK is a 
component of the ILK-pinch-parvin (IPP) protein complex located at focal adhesions (127,128). 
The ankyrin repeats facilitate the interaction with pinch and the C-terminal domain binds the 
adaptor protein, parvin. It is expressed in most mammalian cell types and tissues with the 
greatest expression in cardiac and skeletal muscle (129).  
ILK was originally identified as a kinase due to the significant sequence homology of the 
C-terminus to other Ser/Thr protein kinases (129). Since then, several lines of evidence have 
confirmed that ILK does not possess an active kinase domain and it has since been classified as a 
bona fide pseudokinase (130,131). The identification as a pseudokinase arose as the result of 
genetic studies in C. elegans and D. melanogaster in which kinase dead mutants were capable of 
rescuing the phenotypes caused by ILK deletion (132,133). The pseudokinase domain of ILK is 
an essential domain for the recruitment of several adaptor proteins and signaling molecules 
including several proteins involved in insulin action such as PKB/Akt, PDK1 and GSK-3β. 
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Moreover, ILK is connected to growth factor receptors through the adaptor protein Nck2 (134). 
Therefore although ILK lacks intrinsic kinase activity, it has been shown to regulate the 
activation of numerous intracellular growth factor signaling cascades (135-137).  
 
Integrins regulate insulin signaling and insulin action in several metabolic tissues  
Integrins can work with growth factors to promote phosphorylation or activation of 
receptor tyrosine kinases (138). Engagement of the αvβ3 integrin results in an increase in insulin-
stimulated DNA synthesis (139-141). Insulin receptors rapidly associate with integrins at focal 
adhesions upon tyrosine phosphorylation (141). Additionally, integrin engagement is thought to 
play a stimulatory role in insulin signaling (142). Integrin engagement promotes the activation of 
both insulin receptor substrate (IRS)-1-associated phosphatidylinositol-3 (PI3)-kinase activity 
and Akt activity (142).   
Several studies have established a role for FAK in the regulation of insulin signaling 
(125,143-145). A mammalian two-hybrid system showed that FAK binds to IRS-1 and FAK co-
immunoprecipitates with IRS-1 in 293 cells suggesting this interaction may occur in vivo (146). 
FAK has also been shown to phosphorylate IRS-1 in both a Src-dependent and Src-independent 
manner. FAK interacts with Src in CHO cells and this facilitates IRS-1 phosphorylation (146). 
Moreover, FAK has also been shown to phosphorylate IRS-1 in the absence of Src in human 
embryo kidney cells (146). 
FAK has been implicated in the regulation of glucose homeostasis and insulin action in 
both muscle and liver (144,147-149). FAK tyrosine phosphorylation is decreased in muscle from 
HF-fed Sprague-Dawley rats (147). The in vivo siRNA-mediated knockdown of FAK results in 
hyperglycemia, hyperinsulinemia, and impaired glucose tolerance in mice fed a chow diet (144). 
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The metabolic impairments in these mice were associated with decreased IRS-1 tyrosine and Akt 
Ser473 phosphorylation in both the muscle and liver. The overexpression of FAK in C2C12 cells 
increases insulin-stimulated glucose uptake (150). Conversely, C2C12 skeletal muscle cells 
transfected with siRNA against FAK exhibit decreased insulin-stimulated glucose uptake (147). 
L6 myocytes transfected with antisense FAK display decreased insulin-stimulated IRS-1, IRS-2, 
Akt and GSK-3 phosphorylation associated with decreased insulin-stimulated glucose uptake, 
decreased glycogen synthesis and impaired Glut4 translocation (148). Moreover, FAK undergoes 
rapid tyrosine phosphorylation in livers from healthy rats upon insulin stimulation under 
euglycemic conditions in vivo (149). This is consistent with another study showing that HepG2 
cells transfected with mutant FAK constructs display decreased Akt Ser473 and GSK-3 Ser9 
phosphorylation (125). The observed decrease in GSK-3 phosphorylation was associated with 
decreased insulin-stimulated glycogen synthase activity. There was no difference in the 
phosphorylation of insulin receptor β or PI3K activity upon insulin stimulation. This suggests 
that the effect of FAK on insulin-stimulated glycogen synthesis is downstream of the insulin 
receptor and PI3K. The absence of FAK affecting insulin receptor phosphorylation is consistent 
with other studies indicating that FAK exterts its actions on insulin signaling downstream of the 
insulin receptor (151). Finally, fa/fa rats treated with a TNF-α neutralizing agent exhibited 
increased hepatic FAK phosphorylation associated with decreased hepatic glucose output during 
an insulin clamp (149,152). 
Little is known about the role of ILK in the regulation of insulin action. Considering that 
it is a scaffolding protein, it has been proposed that ILK modulates intracellular signaling 
through its ability to recruit a kinase or multiple kinases into a multiprotein complex. This 
complex then facilitates the activation of downstream signaling molecules upon insulin 
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stimulation. Nonetheless, the presence of ILK has been shown to modulate the activation of key 
insulin signaling molecules such as Akt and GSK-3β. Overexpression of ILK or insulin 
treatment results in increased GSK-3 and Akt phosphorylation (153). Cotransfection of Akt with 
wild-type ILK in 293 cells resulted in an enhancement of phosphorylation of Akt Ser473 (153). 
Several studies have shown that the ablation of ILK results in decreased Akt Ser473 
phosphorylation (154-156). For example, knockdown of ILK expression in HEK-293 and PC3 
cells or the genetic deletion of ILK using Cre recombinase in macrophages resulted in decreased 
Akt Ser473 phosphorylation (154,157). The activation of hepatic stellate cells in rats using CCl4 
resulted in increased ILK protein expression associated with enhanced phosphorylation of Akt, 
p38, and ERK1/2 while the inhibition of ILK by siRNA prevented these signaling changes (158). 
In contrast, the phosphorylation of Akt Ser473 is not affected in mice with a hepatocyte-specific 
deletion of ILK (159) and ILK-deficient cells are capable of phosphorylating Akt at both Thr308 
and Ser473 upon insulin stimulation in a robust manner similar to control cells (160). Thus the 
role of ILK in the regulation of Akt and GSK-3 phosphorylation is debatable and more studies 
need to be performed to address whether ILK mediates phosphorylation of Akt and GSK-3 upon 
insulin stimulation in vivo.  
 
Hypotheses 
The liver extracellular matrix (ECM) expands with high fat (HF) feeding as evidenced by 
increased collagen gene expression and protein expression. Integrins transduce signals from the 
ECM to the cytosol. I hypothesize that the ECM contributes to the pathogenesis of hepatic 
insulin resistance through integrin signaling. As a corollary, I hypothesize that integrin signaling 
regulates hepatic insulin action and lipid metabolism in the context of HF feeding. Integrin α1β1 
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is the only known collagen binding integrin expressed on the hepatocyte. The results of the 
dissertation show that integrin α1 protein expression is upregulated with HF feeding in 
hepatocytes. Thus I hypothesize that integrin α1 is upregulated in hepatocytes as an important 
adaptive response to over nutrition and this protects the liver against metabolic impairments in 
HF-fed C57BL/6J mice. To address this, mice with a deletion of the integrin α1 subunit were 
utilized to determine the role of integrin α1β1 in hepatic glucose and lipid metabolism in vivo. 
Integrins signal through two main proteins: FAK and ILK. The results in Chapter III show that 
there is no difference in FAK activation between HF-fed integrin α1-null mice and wild-type 
littermates. Thus, I hypothesize in Chapter IV that integrin α1β1 signals through ILK to protect 
against hepatic insulin resistance in HF fed mice. To test this hypothesis, mice with a hepatocyte-
specific deletion of ILK were generated and hepatic insulin action and lipid metabolism were 
assessed in vivo. This study was significant as it showed that integrin α1β1 does not signal 
through ILK to protect against hepatic insulin resistance and ILK is in fact a major contributor to 
diet-induced hepatic insulin resistance and lipid accumulation in high fat fed mice.    
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Chapter II 
 
 
RESEARCH MATERIALS AND METHODS 
 
Mouse Models 
All animal protocols were approved by the Vanderbilt University Institutional Animal 
Care and Use Committee and conducted in Association for Assessment and Accreditation of 
Laboratory Animal Care-accredited facilities. Mice were housed in a temperature and humidity 
controlled environment with a 12:12-h light-dark cycle. Mice with a global deletion of integrin 
α1 were studied in Chapter III. Littermate wild-type (itgα1+/+) and integrin α1-null (itgα1-/-) male 
mice were kindly provided by Dr. Ambra Pozzi (98). Mice were backcrossed on to a C57BL/6J 
background for at least 10 generations. Mice with a hepatocyte-specific deletion of integrin-
linked kinase (ILK) were studied in Chapter IV. Mice carrying an ILK allele flanked by loxP 
sites (ILK
lox/lox
, kindly provided by Dr. Roy Zent) (161) were crossed to transgenic mice 
expressing Cre recombinase under the control of the albumin (Alb) promoter (purchased from 
Jackson Laboratory) to generate ILK
lox/lox
Albcre mice and wild-type littermates, ILK
lox/lox
 mice. 
The efficiency of recombination of the Alb promoter increases progressively with age (60). The 
efficiency at birth is approximately 40%. It increases to 75% at weaning (3 weeks of age) and 
completes by 6 weeks of age. For all studies, mice were weaned at 3 weeks of age and separated 
by gender. Mice were fed a standard chow diet (5.5% fat by weight; 5001 Purina Laboratory 
Rodent Diet) or high fat diet (60% kcal from fat; F3282 BioServ) for 16 weeks. All studies were 
performed between 19-24 weeks of age. Mice were weighed and handled weekly to monitor 
body weight and minimize stress due to handling during studies.   
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Surgical Procedures and Body Composition 
A detailed protocol of the surgical procedure is available online through the Vanderbilt 
Mouse Metabolic Phenotyping Center website for their annual course titled: Glucose Clamping 
the Conscious Mouse (www.mc.vanderbilt.edu/mmpc)(162). Briefly, mice were anesthetized 
using isofluorane. The surgical site was prepared by removing hair and washing the skin with 
betadine followed by alcohol. Ketoprofen (5-10 mg/kg) was administered subcutaneously. A 
small midline incision was made 5 mm to the xiphoid process. The left carotid artery was 
exposed, isolated and the cephalic end was ligated with silk suture. Another piece of suture was 
loosely knotted on the caudal end of the exposed artery. The vessel was clamped with micro-
serrefine and cut below the ligated end with spring scissors. The catheter was inserted as far as 
possible prior to the release of the clamp. The catheter was then inserted into the tip of the aortic 
arch. Both ligatures were securely tied and catheter sampling was confirmed. A separate incision 
was made 5 mm to the right of the midline and about 2 mm caudal to the first incision. The right 
jugular vein was exposed and the cephalic end was ligated with silk suture. Another piece of 
suture was loosely tied at the caudal end of the exposed vein and a cut was made below the 
cephalic ligature with spring scissors. The catheter was inserted into the bead and sampling was 
confirmed. The mouse was turned over onto its stomach and a small incision was made between 
the shoulder blades. A 14-gauge needle was tunneled under the skin and through the incision on 
the back. Catheters were threaded through the needle to exteriorize them to the back of the 
mouse. The ventral incisions were closed with nylon suture. The venous catheter was clamped 
with micro-serrefine at the incision site between the shoulder blades. The catheter was cut 1 cm 
above the clamp and connected to a MASA
TM
. The venous catheter and arterial catheters were 
secured to the MASA
TM
 with silk suture. The dorsal incision was closed with nylon and the 
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patency of both catheters was confirmed. The mouse was placed in a warmed, clean cage and 
allowed to recover for 5-6 days prior to study. Body composition was assessed using a mq10 
nuclear magnetic resonance analyzer (Bruker Optics) in 5-h fasted mice.   
 
In Vivo Experiments 
 
Hepatocyte Isolation 
Mice were anesthetized and their livers were perfused via the portal vein with pre-
warmed (30°C) Liver Perfusion Medium (Gibco) for 10-15 min at a rate of 4-5 mL/min. The 
livers were then perfused with Liver Digest Medium containing collagenase (Gibco) for 15-20 
min at a rate of 4-5 mL/min. After digestion, the livers were removed from the mice, placed in a 
dish containing Liver Digest Media and the hepatic capsule was torn and shaken to free the 
dissociated cells. The cell suspension was filtered through a sterile 150-mesh nylon screen into a 
50 mL sterile Falcon tube and centrifuged at 50g for 2 min at 4°C to collect the cells. The cell 
pellet was resuspended and washed 3 times in HBSS prior to a final resuspension in lysis buffer. 
The supernatant from each centrifugation was collected and combined into a single tube. The 
tube containing the supernatant was centrifuged at 650g for 7 min at 4°C. This pellet consists of 
the non-parenchymal cells including Kupffer cells, stellate cells, erythrocytes and cell debris. 
Proteins were extracted and the cellular protein content was measured using the Bradford Protein 
Assay (Bio-Rad). 
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Glucose Tolerance Tests (GTTs) 
Indwelling carotid artery and gastric catheters were surgically implanted for sampling 
and glucose administration, respectively. The gastric catheter allows mice to absorb glucose via 
physiological mechanisms and avoids a stress response from intraperitoneal injection or gavage. 
Mice were fasted for 5-hs and baseline arterial glucose and insulin measurements were obtained 
through the arterial catheter to prevent handling the mice. Glucose was administered through the 
gastric catheter at a dose of 2g/kg body weight. Arterial glucose was measured at 5, 10, 15, 20, 
30, 45, 60, 90 and 120 min after glucose administration. Arterial insulin levels were assessed 
during the GTT at 10, 30, 60 and 120 min. Plasma insulin was determined by radioimmunoassay 
with assistance from the Vanderbilt Hormone Assay Core.   
 
Hyperinsulinemic-euglycemic clamp (Insulin Clamp) 
Indwelling carotid artery and jugular vein catheters were surgically implanted for 
sampling and infusion 5-6 days before the insulin clamp. Mice were fasted for 5 hours before the 
start of the study. [3-
3H]glucose was primed (2.4 μCi) and continuously infused for a 90-min 
equilibration period (0.04 μCi/min). Baseline measurements were determined in arterial blood 
samples collected at -15 and -5 min for analysis of glucose, [3-
3
H]glucose, free fatty acids 
(FFAs) and insulin. A schematic of the insulin clamp is depicted in Figure 2.1. At t = 0, insulin 
(4mU•kg-1•min-1) was infused at a fixed rate and glucose (D50 mixed with [3-3H]glucose) was 
infused at a variable rate to maintain euglycemia. The mixing of D50 with [3-
3
H]glucose 
prevents deviations in specific activity during the insulin clamp (163). Blood glucose was 
clamped at 150-160 mg/dL in the integrin α1β1 studies (Chapter III) and at 130-140 mg/dL in 
the ILK studies (Chapter IV). Heparinized saline-washed erythrocytes were infused to prevent a  
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Figure 2.1 – Experimental setup for the hyperinsulinemic-euglycemic (insulin clamp). 
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fall in hematocrit. Blood was taken at 80-120 min for the determination of [3-
3
H]glucose. 
Samples for the measurement of arterial insulin and FFAs during the insulin clamp were taken at 
80 and 120 min.             
 
Hepatic Triglyceride Secretion  
Mice with indwelling carotid artery and jugular vein catheters were fasted for 8-hours. 
Baseline arterial plasma triglycerides were determined in samples collected at -30 and 0 min. 
After the 0 min sample, VLDL-TG clearance was blocked by an intravenous injection of 
tyloxapol (500 mg/kg, Sigma). Blood samples were collected at 45 min intervals (0, 45, 90, 135, 
and 180 min post-injection). Plasma triglycerides were assessed using Triglycerides-GPO 
Reagent (Raichem) as described below in the section titled Ex Vivo Experiments. 
 
Ex Vivo Experiments 
 
Processing of Insulin Clamp Plasma Samples 
 
Plasma Radioactivity 
Plasma samples from the insulin clamp studies were deproteinized using equal volumes 
of 0.3N barium hydroxide and 0.3N zinc sulfate. The 
3
H2O that resulted from glycolysis of the 
radioactive glucose tracer was removed from the plasma through drying under vacuum. 
Radioactivity of [3-
3
H]glucose was determined by liquid (Ultima Gold; Packard) scintillation 
counting (Packard TRI-CARB 2900TR) (164). Ra and Rd were calculated using non-steady-state 
equations (165). Endogenous (endo) Ra was determined by subtracting the glucose infusion rate 
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(GIR) during the insulin clamp from the total Ra. Assuming steady state conditions, the equation 
for total Ra can be simplified as:  
Ra = I/SA 
where I is the tracer infusion rate and SA is the specific activity of the tracee (dpm/mg).   
 
Plasma Insulin  
Arterial insulin was determined by sandwich ELISA (ALPCO) per manufacturer’s 
instructions. Ten μl of plasma, standard or control was added to the appropriate well into a 96-
well plate supplied by the manufacturer. The wells of the plate were coated with mouse 
monoclonal antibodies specific for insulin. After addition of the samples, an anti-insulin 
monoclonal antibody conjugated horseradish peroxidase enzyme was added to each well. 
Unbound conjugate was washed from the plate and the wells were incubated with TMB 
substrate. A stop solution was added and the optical density was determined at 450 nm and 590 
nm. The intensity of the optical density read at 450 nm was proportional to the amount of insulin 
in the plasma sample. Basal 5-h fasted insulin levels were calculated as an average of samples 
taken at t = -15 and -5 min. The levels during the insulin clamp were calculated as an average 
between the samples taken at t = 80 and 120 min 
  
Plasma Non-Esterified Free Fatty Acids  
Free fatty acids (FFAs) were assessed using an enzymatic assay (NEFA C Kit; Wako 
Chemicals). Arterial blood samples were collected in EDTA tubes. The tubes were centrifuged at 
13,000 rpm for 1 min and 5 μl of the plasma was pipetted into a tube containing dried down THL 
solution. The NEFA assay is based on the following chemical reactions: 
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NEFA + ATP + CoA-SH    
ACS
     Acyl-CoA + AMP + P 
Acyl-CoA + O2 
      ACOD
      2,3-trans-Enoyl-CoA + H2O2 
2 H2O2 + 4-Aminophenazone + MEHA     
POD
     Quinoneimine-color + 4 H2O 
 
The plate was incubated for 10 min at 37°C and the optical density was determined at 550 nm. 
The intensity of the red coloration was proportional to the NEFA concentration in the plasma 
sample. Basal FFA levels were calculated as an average of samples taken at t = -15 and -5 min. 
The levels during the insulin clamp were calculated as an average between the samples taken at  
t = 80 and 120 min. 
 
Plasma Triglycerides 
Plasma triglycerides were assessed using Triglycerides-GPO Reagent (Raichem) per the 
manufacturer’s protocol. Plasma samples were diluted in water as follows: 
 
Baseline (-30 and 0 min): 1:40 
45 and 90 min: 1:100 
135 and 180 min: 1:200 
The triglyceride standards were prepared and 50 μl of either diluted sample or standard were 
added to the appropriate well of a 96-well plate. Seventy five μl of triglyceride reagent was 
added to the plate. The plate was incubated for 10 min at 37°C.   
 
Triglycerides    
Lipase     
   Glycerol + Fatty Acids 
Glycerol + ATP    
Glycerol kinase        
Glycerol-3-Phosphate + ADP 
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Glycerol-3-Phosphate + O2  
   GPO
     Dihydroxyacetone phosphate + H2O2 
H2O2 + 3-hydroxy-2,4,6-tribomobenzoic acid   
Peroxidase     
  Quinoneimine dye + 2H2O 
 
The absorbance of the quinoneimine dye was determined at 540 nm. The intensity of the color 
produced is directly proportional to the concentration of triglycerides in the sample. The 
triglyceride levels were calculated according to their respective dilutions. For the tyloxapol 
studies, the triglyceride production rate was determined according to the following formula: 
 
TG flux = slope * 0.475 μmol/kg*hour 
where slope (mg/dL/hour) [y-axis is the concentration of triglyceride (mg/dL) and x-axis is time 
(hours)] 
 
Hepatic Triglyceride Content 
Liver triglycerides were quantified using the Triglycerides-Glycerophosphate oxidase 
(GPO) Reagent Set according to the manufacturer’s protocol (Pointe Scientific, Inc.). Seventy to 
ninety mg of frozen liver tissue was digested for 1 hour at 70°C in an equal volume of a 3M 
KOH/Ethanol solution. The tubes were incubated at room temperature overnight at 1g.  The next 
day, the total volume of the solution was brought up to a total volume of 500 μl with 2M Tris-
HCl (pH 7.5). In a new set of tubes, each sample was diluted 1:5 with 2M Tris-HCl (pH 7.5). In 
a third set of tubes, 1 mL of GPO reagent was prewarmed at 37°C for 5 min. Ten μl of the 
diluted sample was added to each tube and the reaction was incubated for another 5 min at 37°C. 
A standard curve was prepared in a separate set of tubes with prewarmed GPO reagent. Two 
hundred μl of the reagent mixture was added to a 96-well plate. The GPO assay is based on the 
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chemical reactions as described above under the section titled Plasma Triglycerides. The 
absorbance of the quinoneimine dye was determined at 540 nm. The intensity of the color 
produced is directly proportional to the concentration of triglycerides in the sample. 
 
Hepatic Diglyceride Content 
Liver diglycerides were extracted with the assistance from the Vanderbilt Lipid Core 
using the method of Folch-Lees (166). Phospholipids, diglycerides, triglycerides and cholesteryl 
esters were scraped from the plates and methylated using BF3 /methanol as described by 
Morrison and Smith (167). The methylated fatty acids were extracted and analyzed by gas 
chromatography.  Gas chromatographic analyses were carried out on an Agilent 7890A gas 
chromatograph equipped with flame ionization detectors, a capillary column (SP2380, 0.25 mm 
x 30 m, 0.25 µm film, Supelco, Bellefonte, PA). Helium was used as a carrier gas. The oven 
temperature was programmed from 160°C to 230°C at 4°C/min. Inclusion of lipid standards with 
odd chain fatty acids permitted quantitation of the amount of lipid in the 
sample. Dipentadecanoyl phosphatidylcholine (C15:0), diheptadecanoin (C17:0), trieicosenoin 
(C20:1), and cholesteryl eicosenoate (C20:1) were used as standards.  
 
Plasma β-hydroxybutyrate 
Plasma β-hydroxybutyrate (β-OH) levels were determined in samples from 5-h fasted 
mice using the β-OH (Ketone Body) Colormetric Assay Kit (Cayman Chemical Company) per 
the manufacturer’s protocol.  Plasma was diluted 1:5 in assay buffer.  Fifty μl of the plasma 
mixture or standard was added to the appropriate well of a 96-well plate.  The β-OH assay is 
based on the following chemical reactions: 
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β-OH + NAD+    β-OH dehydrogenase     Acetoacetate + NADH + H+ 
WST-1 + NADH   
Diaphorase        
WST-1 Formazan + NAD
+
 
 
The absorbance of the formazan dye was determined spectrophotometrically at 445 nm. The 
absorbance of the dye was directly proportional to the β-OH concentration in the plasma. 
 
Oil Red O Staining 
Neutral lipids were stained with oil red O with assistance from the Vanderbilt 
Translational Pathology Shared Resource Core. Fresh liver pieces were embedded in OCT, flash 
frozen on dry ice and stored at -80°C until processing. Liver sections were cut and mounted to 
slides. Slides with liver samples were incubated in 100% propylene glycol prior to a 4 hour 
incubation in a filtered oil red o solution. The samples were washed in 85% propylene glycol, 
counterstained in hematoxylin and mounted. Images were obtained using an Olympus upright 
microscope. 
 
Hepatic Glycerol-3-Phosphate  
Glycerol-3-Phosphate (G3P) was determined in frozen liver tissue from 5-h fasted mice 
using the Glycerol-3-Phosphate Colormetric Assay Kit (BioVision) per the manufacturer’s 
protocol.  Approximately 30 mg of frozen liver tissue from 5-h fasted mice was homogenized in 
200 μl G3P assay buffer on ice.  The lysate was centrifuged at 12000 rpm at 4°C.  Five μl of the 
supernatant was added to the appropriate well of a 96-well plate and the volume was brought up 
to 50 μl with G3P assay buffer.  Fifty μl of the G3P reaction mix was added to each well 
containing the standard and sample wells.  The plate was incubated at 37°C for 40 min and the 
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absorbance was determined at 450 nm. The G3P assay is based on the following chemical 
reactions: 
 
Glycerol-3-Phosphate     
G3P Enzyme Mix          
Intermediate    
G3P Probe      
 Color detection 
 
Mitochondrial Oxygen Consumption and Enzymatic Activity 
Mice were fasted for 5-h prior to cervical dislocation. For the integrin α1 studies (Chapter 
III), fresh liver samples were mechanically permeabilized (168). Mechanically permeabilized 
liver pieces were used in lieu of isolated mitochondria to ensure the cytoskeletal attachments are 
conserved and the mitochondria are not stressed during the functional measurements. For the 
ILK studies (Chapter IV), mitochondria were isolated from fresh liver tissue using standard 
homogenization and differential centrifugation methods as previously described (169). Briefly, 
liver tissue was minced in 5 mL ice-cold mitochondrial isolation buffer containing 250 mM 
sucrose, 2 mM KH2PO4, 1 mM EGTA and 20 mM Tris-HCL (pH 7.2). The minced liver tissue 
was rinsed twice and resuspended in 4.5 mL ice-cold mitochondrial isolation buffer. The tissue 
was homogenized at 150 rpm in a pre-chilled Teflon Potter-Elvehjem pestle for 2 up and down 
passes. The homogenate was centrifuged for 10 min at 2200 rpm at 4°C. The mitochondria-
enriched supernatant was centrifuged for 10 min at 9400 rpm at 4°C. The mitochondrial pellet 
was resuspended in 1 mL mitochondrial isolation buffer and centrifuged for a second time for 10 
min at 9400 rpm at 4°C. The final pellet was resuspended in 200 μl mitochondrial isolation 
buffer. Mitochondrial protein concentration was determined using the BCA protein assay. In all 
studies, oxygen consumption was measured in air-saturated MiR05 (pH 7.4, 30°C) with a Clark-
type oxygen electrode (Oroboros Instruments Corp., Innsbruck, Austria). State 2 respiration was 
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measured in the presence of either 10 mM glutamate and 2 mM malate or 2 mM malate and 50 
μM palmitoyl carnitine prior to the addition of ADP. State 3 respiration was measured upon the 
addition of 0.5 mM ADP. Cytochrome c (10 μM) was added at the end of each measurement to 
ensure the outer mitochondrial membrane was intact. The following criteria were applied for the 
inclusion of each respiration measurement: a respiratory control ratio (RCR) at or above 4 and 
less than 10% response to cytochrome c addition. The RCR was calculated as state 3/state 2. 
Citrate synthase activity (CSA) was measured in liver homogenate according to the method of 
Srere (170). Respiration measurements were normalized to CSA for the integrin α1 studies. For 
the ILK studies, respiration measurements were normalized to mitochondrial protein 
concentration.   
 
Hepatic Glycogen Content 
Liver glycogen content was determined in 5-h fasted and insulin clamped livers as 
previously described (171). Approximately 40-60 mg of frozen liver tissue was homogenized in 
0.03N HCl (0.1 mg tissue/ul HCl) and incubated at 80°C for 10 min. Two hundred μl of the 
digest was transferred to chromatography paper strips. The paper strips were washed 3x for 40 
min per wash in 70% ethanol using a stir plate. After the last wash, the ethanol was poured off 
and the strips were briefly rinsed with acetone. The strips were dried in a ventilation hood 
overnight. The next day, the dried strips were placed in tubes containing 5 mL of 
aminoglucosidase solution (20 mg aminoglucosidase, 100 mL 0.2 M NaOAc buffer and 400 mL 
distilled water) and incubated in a 37°C shaking water bath for 3 hours. For both the 5-h fasted 
and insulin clamped livers, the glucose concentration was determined enzymatically in a 96-well 
place at 340 nm at the end of the incubation period. The following reaction was used: 
45 
 
Glucose + ATP    
Hexokinase
     Glucose-6-phosphate +ADP 
Glucose-6-phosphate +ADP
       G6PDH
      phospho-D-gluconolactone + NADPH 
 
Standard glucose concentrations were used to measure known equivalent NADPH, which was 
used to generate a standard curve for the measurement of the absorbance for the glucose 
concentrations of each sample. For the insulin clamped livers, the rate of glucose incorporated 
into glycogen during the insulin clamp was also determined by liquid scintillation counting. 
Briefly, 3 mL of the solution from the aminoglucosidase incubation was added to a scintillation 
vial with 15 mL scintillation fluid (Ultima Gold; Packard) and counted.   
 
Hepatic Hydroxyproline Content 
Hydroxyproline was determined in frozen livers from 5-h fasted mice using the 
Hydroxyproline Assay Kit (Sigma-Aldrich) per manufacturer’s instructions. Approximately 50 
mg of frozen liver tissue from 5-h fasted mice was homogenized in distilled water. Two hundred 
μl of the lysate was combined with 200 μl 12N HCl. The samples were hydrolyzed at 120°C for 
3 hours. Twenty μl of lysate was added to a 96-well plate. The plate was incubated in an oven at 
60°C for 1 hour to dry the samples. One hundred μl of the ChloramineT/Oxidation buffer was 
added to each sample and standard well, and the plate was incubated at room temperature for 5 
min. One hundred μl of Diluted 4-(Dimethylamino) benzaldehyde (DMAB) Reagent was added 
to each standard and sample well, and the plate was incubated for 90 min at 60°C. The 
absorbance was determined at 560 nm. Hydroxyproline concentration was determined by the 
reaction of oxidized hydroxyproline with DMAB.   
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Immunoprecipitation and Immunoblotting 
Frozen liver tissue was homogenized in a buffer containing 25 mM Tris-HCl (pH 7.4), 10 
mM EDTA, 10% glycerol, 1% Triton X, 50 mM sodium pyrophosphate, 100 mM sodium 
fluoride, 1 mM PMSF and Halt Protease and Phosphatase Inhibitor (Thermo Scientific). For 
immunoprecipitation of the insulin receptor, 1 mg of protein was incubated with antibodies 
against the insulin receptor (Cell Signaling). Samples were incubated at 4°C overnight with 
Protein A/G PLUS-Agarose Immunoprecipitation Reagent (Santa Cruz Biotechnology). The 
immunoprecipitates were collected via centrifugation, applied to SDS-PAGE gels and transferred 
to PVDF membranes. Immunoblots were incubated with primary antibodies against the insulin 
receptor (Cell Signaling) and phosphotyrosine (Santa Cruz Biotechnology). For traditional 
immunoblots, the following primary antibodies were used: pAkt (Ser
473
 and Thr
308
, Cell 
Signaling), total Akt (Cell Signaling), pIRS1 (Tyr
612
, Life Technologies), total IRS1 (Cell 
Signaling), pERK1/2 (Thr
202
/Tyr
204
 Cell Signaling), total ERK 1/2 (Cell Signaling), pJNK1/2 
(Thr
183
/Tyr
185
, Cell Signaling) pFAK (Tyr
397
, Abcam), total FAK (Santa Cruz), pFoxo1 Ser
253
,
 
total Foxo1 (Santa Cruz), integrin α1 (Chemicon), collagen I (Santa Cruz Biotechnology), 
collagen IV (Meridian), α-parvin (Cell Signaling), PINCH (BD Biosciences) and β-actin (Cell 
Signaling). Imaging and densitometry were performed using the ImageJ program and Odyssey 
imaging system (LI-COR Biosciences). 
 
Immunohistochemistry 
Collagen I was assessed by immunohistochemistry in paraffin-embedded tissue sections 
with assistance from the Vanderbilt Translational Shared Pathology Resource Core. Sections 
(5μm) were incubated with anti-collagen I antibody for 60 min prior to staining with 
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hematoxylin. The EnVision+HRP/DAB System (DakoCytomation) was used to produce 
staining. Images were obtained using a Q-Imaging Micropublisher camera mounted on an 
Olympus upright microscope.     
 
Real-time Polymerase Chain Reaction 
RNA was extracted using the RNeasy Mini Kit (Qiagen). RNA was reverse transcribed 
using the iScript cDNA synthesis kit (Bio-Rad). Quantitative PCR was performed using TaqMan 
Universal PCR Master Mix and commercially available TaqMan Assays (Applied Biosystems) 
on the CFX Real Time PCR Instrument (Bio-Rad) for all genes except for Dgat1 and Dgat2. 
Data were normalized to the 18S ribosomal protein. Gene expression for Dgat1 and Dgat2 was 
measured using SYBR Green as previously described (172). Data were analyzed using the 2
-ΔΔCt
 
method (173).   
 
Kinexus Assay 
The Kinex Kam-850 Antibody Microarray Kit (Kinexus) was used to monitor expression 
levels and phosphorylation states of signaling proteins per manufacturer’s instructions. Two-
hundred and fifty mg of pooled frozen 5-h fasted insulin clamped liver tissue from each genotype 
was homogenized and needle sheered in 1 mL of lysis buffer. The homogenate was centrifuged 
at 13000 rpm for 30 min at 4°C. The supernatant was collected and the protein concentration was 
determined using the BCA protein assay. Fifty μg of lysate from each genotype was labeled with 
the Kinex 543 Labeling Dye and the proteins were purified using Microspin G-25 Columns. The 
full amount of each labeled protein sample was applied to the microarray slide. The slide was 
incubated in a humidity chamber in the dark on a table top shaker for 2 hours at room 
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temperature. The slide was washed several times and dried in a swing-bucket bench top 
centrifuge. The microarray slide was shipped to Kinexus for quantitation and data analysis. 
Signal quantification was performed using ImaGene 9.0 from BioDiscovery. Z scores were 
calculated by subtracting the overall average intensity of all spots within a sample from the raw 
intensity for each spot, and dividing it by the standard deviations of all measured intensities 
within each sample (174). A Z ratio of ± 1.2 to 1.5 is considered significant.  
 
Statistical analysis 
Data are presented as means ± SEM. Statistical analyses were performed using Student t 
test or two-way ANOVA followed by Tukey post hoc tests as appropriate. The significance level 
was P ≤ 0.05. 
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Chapter III 
 
 
INTEGRIN α1-NULL MICE EXHIBIT IMPROVED FATTY LIVER WHEN FED A 
HIGH FAT DIET DESPITE SEVERE HEPATIC INSULIN RESISTANCE 
 
Aims 
Hepatic insulin resistance is associated with increased collagen. Integrin α1β1 is the only 
collagen binding receptor expressed on hepatocytes. The studies described in this chapter show 
that integrin α1 protein expression is increased in hepatocytes isolated from HF-fed mice 
compared to chow fed controls. The goal of Chapter III was to determine whether the 
upregulation of integrin α1 in response to a HF diet exerts a protective effect against the 
detrimental effects of a HF diet in the liver through increased signal transduction (Figure 3.1).  
 
Introduction 
The prevalence of Type 2 diabetes (T2D) has increased dramatically in parallel with 
excess caloric intake and sedentary lifestyles. Insulin resistance precedes the development of 
T2D (1,2). The liver, as one of the major insulin responsive organs, contributes to the 
pathogenesis of insulin resistance (32,175). Hepatic insulin resistance is strongly correlated with 
hepatic lipid accumulation. In rats, three days of high fat (HF) feeding leads to a 3-fold increase 
in hepatic triglyceride (TG) accumulation and decreased suppression of hepatic glucose 
production during an insulin clamp (51). In addition, hepatic lipid accumulation is associated 
with liver damage and increases in extracellular matrix (ECM) collagen proteins (32,73,86,175). 
Liver biopsies from humans with and without T2D demonstrate that the livers from diabetic 
patients exhibit severe steatosis associated with increased collagen IV protein expression (88). 
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Figure 3.1 – Scheme of the hypothesis presented in Chapter III. In wild-type C57BL/6J mice on 
a normal chow diet, there is some collagen present and when bound to integrin α1β1, this results 
in signal transduction in the hepatocyte. Under conditions of high fat feeding, hepatic collagen 
content expands and there is increased integrin α1 protein expression on hepatocytes. This results 
in increased hepatocyte signal transduction. When integrin α1-null mice are fed on a high fat 
diet, there is an increase in hepatic collagen content but there is no integrin α1β1 present. This 
results in no integrin α1β1 signal transduction within the hepatocyte and metabolic impairments 
within the liver.  
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      ECM production and degradation are controlled by integrins, transmembrane receptors 
for ECM proteins that consist of an α and β subunit (92). Upon ligand binding, integrins 
transduce signals across the plasma membrane to facilitate outside-in cell signaling (113). 
Several studies have suggested a role for integrins in the promotion of insulin action 
(92,142,146,176,177). Integrin α5β1 binding to its ligand fibronectin enhances insulin-stimulated 
tyrosine phosphorylation of both the insulin receptor and IRS1 (176). β1-integrin activation 
through its engagement with an anti-β1-integrin antibody or fibronectin leads to IRS1, PI3-
kinase and subsequent Akt activation in isolated rat adipocytes (142). The integrin signaling 
molecule, focal adhesion kinase (FAK) has been shown to directly bind to IRS-1 and lead to 
IRS-1 tyrosine phosphorylation in intact cells (146). Finally, the loss of the integrin β1 subunit in 
striated muscle leads to insulin resistance and decreased muscle glucose uptake (177).   
Integrin α1β1 is a major collagen receptor expressed on various cell types, including 
hepatocytes (102). The expression of integrin α1β1 is upregulated in the course of hepatic injury 
and ECM remodeling (110). We previously showed that the global deletion of the integrin α1 
subunit leads to severe impairments in insulin-induced suppression of glucose production in HF-
fed mice (178). However, the mechanism for this effect and the broader role of integrin α1 in the 
pathogenesis of HF diet-induced hepatic insulin resistance and lipid accumulation is unknown. 
In these studies we show that integrin α1 protein expression is upregulated with HF 
feeding in hepatocytes. Thus, we assessed glucose tolerance and insulin sensitivity in HF-fed 
integrin α1-null (itga1-/-) and wild-type littermates (itgα1+/+) to determine whether this response 
belies a protective effect against hepatic metabolic impairments in C57BL/6J mice. We show 
that deletion of integrin α1 results in severe hepatic insulin resistance as evidenced by complete 
alleviation of the insulin-mediated suppression of hepatic glucose production and decreased 
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hepatic insulin signaling. The severe hepatic insulin resistance in HF-fed itga1-/- mice was 
present despite a ~50% decrease in hepatic TG and DAG accumulation. The reduction in hepatic 
lipids was associated with a combination of decreased FFA availability upon insulin stimulation, 
decreased gene expression of the fatty acid transporter Cd36 and increased mitochondrial fatty 
acid utilization. This indicates that the decrease in hepatic lipid accumulation in HF-fed itga1-/- 
mice may be attributed to altered fatty acid metabolism. 
 
Experimental Design 
Littermate wild-type (itga1
+/+) and integrin α1-null (itga1-/-) male mice on a C57BL/6J 
background were fed either a standard chow diet (5.5% fat by weight; 5001 Purina Laboratory 
Rodent Diet) or HF diet (60% kcal from fat; F3282 BioServ) for 16 weeks. All studies were 
performed between 19 and 24 weeks of age. Insulin action was assessed using the insulin clamp 
combined with tracer techniques to determine sites of insulin resistance. See Chapter II for 
detailed methods. 
 
Results 
 
Collagen gene expression and hydroxyproline content are elevated in livers from HF-fed 
C57BL/6J mice 
 Gene expression for collagen I α1, collagen I α2 and collagen III α1 was increased in HF-
fed mice compared to chow-fed mice (Figure 3.2A). The increase in collagen gene expression 
correlated with an increase in hydroxyproline content (Figure 3.2B).  
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Figure 3.2 – Collagen gene expression and hydroxyproline content in livers from 5-h fasted 
wild-type C57BL/6J mice on a chow or high fat diet. Data are represented as means ± SEM;  
n = 4-5/group. *p < 0.05 chow vs. high fat fed. 
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Integrin α1 protein expression is increased in hepatocytes isolated from HF-fed C57BL/6J 
mice 
The upregulation of the integrin α1 subunit has been described in several states of chronic 
liver disease associated with inflammation and fibrosis (110). To determine the effect of HF 
feeding on hepatocyte integrin α1 expression, hepatocytes were isolated from both chow and HF-
fed C57BL/6J wild-type mice. Integrin α1 protein expression was increased ~2 fold in isolated 
hepatocytes from HF-fed mice (Figure 3.3A and B). TGF-β signaling is associated with the 
synthesis of hepatic collagen in rodents fed a HF diet (179). In addition, this cytokine promotes 
the expression of integrin α1 (109). Thus, we analyzed the activation of the TGF-β signaling 
cascade by evaluating TGF-β gene expression and the phosphorylation status of the downstream 
activator Smad2. We found that TGF-β gene expression was increased in the livers of HF fed 
mice (Figure 3.3C). In support of the notion that TGF-β signaling is increased with HF-feeding 
along with our observation that integrin α1 protein expression is increased in HF-fed mice, we 
also found that Smad2 activation (represented as the ratio of pSmad2/Smad2) was increased in 
the livers of HF-fed mice compared to their lean littermate controls (Figure 3.3D and E).    
 
Adaptations to the genetic deletion of integrin α1 in both chow and HF-fed mice 
To determine the role of integrin α1 in the livers of HF-fed mice, itgα1+/+ and itga1-/- 
mice were fed a HF-diet for 16 weeks. HF feeding increased body weight, % fat mass and fasting 
blood glucose (Table 3.1). Body weight did not differ between genotypes on their respective 
diets. Fat mass was decreased in the HF-fed itga1-/- mice compared to HF-fed itgα1+/+ mice. HF 
feeding increased fasting glucose and fasting insulin in wild-type mice. Fasting glucose was not 
different between the genotypes on their respective diets. Fasting insulin was not different 
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Figure 3.3 – Integrin α1 protein expression is increased in hepatocytes isolated from high fat fed 
mice. (A) Western blot analysis for integrin α1 protein expression in isolated hepatocytes (n = 
5/group). (B) Quantitative analysis of data from A. (C) TGF-β gene expression in whole liver 
homogenate from 5-h fasted mice fed either a chow or high fat diet for 16 weeks (n = 5-6/group). 
(D) Smad2 activation in whole liver homogenate from 5-h fasted mice fed either a chow or high 
fat diet for 16 weeks (n = 4/group). (E) Quantitative analysis of data from D. Integrated 
intensities were obtained by the Odyssey and Image J software. Integrin α1 protein expression 
was normalized to β-actin. Smad2 activated was calculated as the ratio of p-Smad2 to total 
Smad2. Data are represented as means ± SEM; n = 4-5. *p < 0.05 chow vs. high fat fed. 
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Table 3.1 
Characteristics of wild-type (itgα1+/+) and integrin α1 null mice (itgα1-/-) mice on both a chow 
and high fat (HF) diet.   
 
 
 Chow High fat 
 itgα1+/+ itgα1-/- itgα1+/+ itgα1-/- 
Weight (g) 26.1 ± 0.5 27.0 ± 0.5 48.4 ± 0.9 * 48.9 ± 1.3
†
 
Fat mass (%) 10.4 ± 0.5 11.5 ± 2.0  41.6 ± 0.7 * 39.0 ± 1.8 
§
 
Fasting glucose (mg/dL)  118 ± 3  111 ± 7  147 ± 12 *   151 ± 5
†
 
Fasting insulin (ng/mL) 0.80 ± 0.2 0.82 ± 0.1 2.12 ± 0.21* 3.44 ± 0.72 
§
 
 
 
 
Body composition, fasting glucose and insulin were determined in basal 5-h fasted mice  
(n = 6-8/group). Data are represented as means ± SEM. *p < 0.05 chow-fed itgα1+/+ vs. HF-fed 
itgα1+/+, †p < 0.05 chow-fed itga1-/- vs. HF-fed itgα1-/-and §p < 0.05 HF-fed itgα1+/+ vs. HF-fed 
itgα1-/-. 
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 between the genotypes on a chow diet, however it was elevated in HF-fed itga1-/- mice 
compared to HF-fed itgα1+/+ mice indicating insulin resistance.  
HF feeding leads to excessive accumulation of collagen in the liver (86,87). Integrin α1β1 
down regulates collagen synthesis, however its contribution to hepatic collagen gene expression 
in the HF-fed state has not been investigated (180). Therefore we measured collagen gene 
expression in itgα1+/+ and itga1-/- mice on both a chow and HF-fed diet (Table 3.2). Gene 
expression for collagen I α1, collagen I α2 and collagen III α1 was increased in chow-fed itga1-/- 
mice compared to chow-fed itgα1+/+ mice. Gene expression for collagen I α1 and collagen I α2 
was increased by HF feeding in itgα1+/+ mice. There was no difference in collagen mRNA levels 
between chow-fed and HF-fed itga1-/- mice. Next, we investigated whether the changes in 
collagen I gene expression resulted in differences in protein expression through western blot 
analysis and immunohistochemistry (Figure 3.4). Consistent with the collagen I gene expression 
results, we found that collagen I protein expression was also increased in the itga1-/- mice 
compared to itgα1+/+ mice regardless of diet using western blot analysis (Figure 3.4A). Collagen 
I immunohistochemistry in the liver was used to determine the localization of the collagen 
deposition (Figure 3.4B). Collagen I staining was most prevalent around the vessels and within 
the sinusoidal spaces in all conditions. Thus, deletion of integrin α1 leads to increased hepatic 
collagen gene and protein expression independent of diet. 
 
Integrin α1-null mice on a HF diet exhibit severe hepatic insulin resistance 
Fasting insulin levels are increased in HF-fed itga1-/- mice compared to HF-fed itgα1+/+ 
mice indicating impaired glucose metabolism. Therefore we examined glucose tolerance in both 
chow and HF-fed itgα1+/+ and itga1-/- mice using gastric catheters for the delivery of glucose 
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Table 3.2 
Collagen mRNA levels: interaction of gene and diet. 
 
 
 Chow High fat 
 itgα1+/+ itgα1-/- itgα1+/+ itgα1-/- 
Col I α1 1.1 ± 0.2 3.0 ± 0.6 * 1.5 ± 0.1 * 4.2 ± 1.2 
§
 
Col I α2 1.1 ± 0.3 9.6 ± 3.0 * 2.6 ± 0.6 * 13.6 ± 5.1 
§
 
Col III α1 1.2 ± 0.2 4.0 ± 0.6 * 1.1 ± 0.3 4.5 ± 1.6 
§
 
Col IV α1 1.0 ± 0.1 2.3 ± 0.4 * 1.8 ± 0.5 3.4 ± 1.0 
 
 
Total RNA was extracted from the livers of 5-h fasted mice and reverse transcribed into cDNA.  
Quantitative PCR was used to determine gene expression of several collagen chains (n = 5-
7/group). Data are represented as means ± SEM. *p < 0.05 compared to chow-fed itgα1+/+ mice 
and 
§
p < 0.05 HF-fed itgα1+/+  vs. HF-fed itgα1-/-. 
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Figure 3.4 – Collagen I protein expression is increased in integrin α1 null mice. (A) Western blot 
analysis of collagen I performed on liver homogenates from basal 5-h fasted mice (n = 4/group). 
Integrated intensities were obtained using the Image J software and collagen I protein expression 
was normalized to β-actin. (B) Representative images from immunohistochemical staining of 
collagen I in livers from basal 5-h fasted mice (n = 5-7/group). Data are represented as means ± 
SEM. §p < 0.05 compared to chow-fed itgα1
+/+ 
mice.  
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directly into the stomach. The results from the GTTs indicate that there is no difference in 
glucose tolerance or the insulin response to a glucose challenge (insulin excursion) between the 
genotypes on their respective diets (Figure 3.5A-D). Considering that whole-body glucose 
tolerance can appear normal despite impaired insulin action (181), we next assessed insulin 
action in HF-fed itgα1+/+ and itga1-/- mice using the hyperinsulinemic-euglycemic (insulin) 
clamp. During the insulin clamp, blood glucose was maintained between 150-160 mg/dL (Figure 
3.5E). The steady state glucose infusion rate (GIR) was lower in HF-fed itga1-/- mice (Figure 
3.5F).  There was no difference in fasting endogenous glucose production (endoRa) (Figure 
3.5G). EndoRa during the insulin clamp was suppressed by ~50% in HF-fed itgα1
+/+
 mice. In 
contrast, endoRa was not suppressed at all in HF-fed itga1-/- mice (Figure 3.5G) indicating 
complete resistance to insulin suppression of endogenous glucose production. There was no 
difference in basal or insulin-clamped whole body glucose disappearance (Rd) (Figure 3.5H). 
Plasma insulin during the insulin clamp was not different between the groups (9.65 ± 1.22 vs. 
9.35 ± 1.20 ng/mL). The severe hepatic insulin resistance in HF-fed itga1-/- mice is independent 
of its effects on the transcriptional regulation of collagen as there is no difference in collagen 
gene expression between the chow and HF-fed itga1-/- mice (Table 3.2).   
Integrins, including integrin α1β1, can regulate the phosphorylation and activation state 
of receptor tyrosine kinases and their downstream modulators (139,180,182-184). To determine 
whether genetic deletion of the integrin α1 subunit affected insulin receptor phosphorylation, we 
assessed insulin receptor phosphorylation in insulin clamped livers from HF-fed itgα1+/+ and 
itga1-/- mice. There was no difference in insulin receptor phosphorylation (Figure 3.6A), 
suggesting that integrin α1β1 does not affect insulin-mediated activation of its receptor. To 
determine whether integrin α1β1 affected insulin signaling downstream of the insulin receptor, 
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Figure 3.5 – Integrin α1β1 protects against diet-induced hepatic insulin resistance. Glucose 
tolerance tests (GTT) were performed on chow and HF fed itgα1+/+ and itga1-/- mice. Arterial 
glucose (A and C) and insulin (B and D) were measured during the GTTs (n = 5-7/group). 
Arterial glucose (E) and glucose infusion rate (F) during the hyperinsulinemic-euglycemic 
(insulin) clamp (n = 5-6/group). Mice were fasted for 5-h prior to the start of the insulin clamp. 
Blood glucose was maintained between 150-160 mg/dL during the steady state (80-120 min). 
Glucose (50%) was infused to maintain euglycemia. Endogenous glucose production (endoRa) 
(G) and whole-body disappearance (Rd) (H) were determined during the steady state period of 
the insulin clamp. Data are represented as means ± SEM. *p < 0.05 compared to the basal 
measurement in HF-fed itgα1+/+ mice and §p < 0.05 compared to HF-fed itgα1+/+ mice during the 
insulin clamp. 
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Figure 3.6 – Integrin α1β1 facilitates hepatic insulin action in HF-fed mice. (A) 
Immunoprecipitation (IP) of the insulin receptor (IR) was performed on liver homogenates after 
the insulin clamp prior to an immunoblot for phosphotyrosine (pY) (n = 4/group). IR 
phosphorylation was determined as the ratio of pY to total IR. (B) Representative blots of liver 
insulin signaling after the insulin clamp (n = 4-5/group). (C) mRNA was extracted from both 
basal 5-h fasted and 5-h fasted insulin clamped livers. qPCR was performed to determine gene 
expression of the gluconeogenic genes G6pc and Pepck. (D) Focal adhesion kinase (FAK) and 
FAK phosphorylation was determined in liver homogenates from basal 5-h fasted mice (n = 
4/group). FAK phosphorylation was quantified as the ratio of p-FAK to FAK. Percent increase of 
FAK phosphorylation was calculated relative to wild-type (WT) mice. Integrated intensities were 
obtained by the odyssey and Image J software. Data are represented as means ± SEM. 
§
p< 0.05 
compared to HF-fed itgα1+/+ mice. *p< 0.05 compared to chow-fed itgα1+/+ mice. ∆p < 0.05 
compared to chow-fed itga1-/- mice. 
‡
p < 0.05 compared to basal 5-h fasted mice.  
63 
 
we assessed several markers of insulin signaling in insulin stimulated livers from HF-fed itgα1+/+ 
and itga1-/- mice. Consistent with the hepatic glucose flux measurements, phosphorylation of 
IRS-1 at Tyr
612
 and Akt at Ser
473
 were decreased in HF-fed itga1-/- mice indicating decreased 
insulin action (Figure 3.6B). There was no difference in the insulin-mediated phosphorylation of 
Akt at Thr
308
, Foxo1 at Ser
253
 or FAK at Ser
397
. To determine the effect of integrin α1β1 on 
hepatic gluconeogenic gene expression in the HF-fed state, we used qPCR to determine gene 
expression of glucose-6-phosphatase (G6pc) and phosphoenol pyruvate carboxylase (Pepck) in 
the livers from basal 5-h fasted and insulin clamped mice (Figure 3.6C). Consistent with the 
severe hepatic insulin resistance in the HF-fed itga1-/- mice, insulin failed to suppress G6pc gene 
expression and there was a striking insulin-mediated increase in Pepck gene expression. In 
contrast, insulin-mediated G6pc gene expression was significantly decreased in the HF-fed 
itgα1+/+mice. Consistent with other reports (105,185), we found that deletion of integrin α1 
reduced activation of the MAPK signaling pathway as evidenced by a slight yet non-significant 
decrease in ERK1/2 activation and a significant decrease in JNK1/2 activation (Figure 3.6B).    
Integrin α1β1 signals to activate several downstream targets including FAK (144) and the 
integrin α1 subunit has been shown to bind FAK (122). In addition, FAK has been shown to 
interact with IRS1 (146). Thus we sought to determine whether decreased insulin signaling in the 
HF-fed itga1-/- mice is associated with decreased FAK phosphorylation in both insulin clamped 
and basal 5-h fasted livers. We found that there was no difference in insulin-stimulated FAK 
phosphorylation between the HF-fed itgα1+/+ and itga1-/- mice (Figure 3.6B). In the basal state, 
there was a significant decrease in FAK phosphorylation in HF-fed mice compared to chow-fed 
mice independent of genotype (Figure 3.6D). However, there was no difference in the percent 
increase in pFAK/FAK relative to WT in either the chow-fed or HF-fed mice in the basal 5-h 
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fasted state. Thus, integrin α1β1 appears to mediate insulin signaling in a FAK-independent 
manner. 
 
Genetic deletion of integrin α1 improves fatty liver through changes in fatty acid metabolism 
HF feeding leads to increased hepatic lipid accumulation and severe hepatic insulin 
resistance associated with decreased insulin stimulated IRS1 tyrosine phosphorylation (51). 
Thus, we wanted to assess whether the severe hepatic insulin resistance in HF-fed itga1-/- mice 
could be attributed to increased lipid accumulation. To determine the role of integrin α1 on 
hepatic lipid accumulation, we assessed hepatic triglyceride (TG) and diglyceride (DAG) 
accumulation in the livers from both chow and HF-fed itgα1+/+ and itga1-/- mice. HF feeding 
increased liver TG and DAG content ~ 5 fold in itgα1+/+ mice compared to chow-fed itgα1+/+ 
mice (Figure 3.7A, B and C).  Liver TG and DAG content was decreased by ~ 50% in HF-fed 
itga1-/- mice compared to HF-fed itgα1+/+ mice (Figure 3.7A, B and C). This was supported by 
the finding that lipid droplets were smaller in HF-fed itga1-/- mice compared to HF-fed itgα1+/+ 
mice (Figure 3.7A).        
To examine the potential mechanisms whereby HF-fed itga1-/- mice exhibit decreased 
TG and DAG accumulation, we first investigated several parameters that regulate hepatic 
triglyceride metabolism. Circulating plasma TGs were increased in HF-fed itga1-/- mice (Figure 
3.8A). Thus, we tested the hypothesis that the reduction in liver TGs was due to increased 
secretion from the liver. This hypothesis, however, was not supported by the results as no 
difference in TG secretion was observed between the HF-fed itgα1+/+ and itga1-/- mice (Figure 
3.8B and C). Next we examined the expression of several genes associated with hepatic 
lipogenesis. Despite decreased lipid accumulation, gene expression for the lipogenic genes 
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Figure 3.7 – Integrin α1 promotes hepatic lipid accumulation. (A) Oil red O staining of liver 
neutral lipid droplets. Liver triglyceride (TG) (B) and diglyceride (DAG) (C) content was 
quantified in 5-h fasted mice (n = 5/group). Data are represented as means ± SEM. *p < 0.05 
compared to chow-fed itgα1+/+ mice and §p < 0.05 compared to HF-fed itgα1+/+ mice. 
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Figure 3.8 – Effect of whole-body integrin α1 deletion on triglyceride (TG) metabolism. (A) 
Circulating plasma TGs in basal 5-h fasted mice. (B) Hepatic TG secretion was determined using 
tyloxapol to block VLDL-TG clearance from the circulation. (C) Quantification of triglyceride 
secretion rates. (D) mRNA was extracted from basal 5-h fasted livers and qPCR was used to 
determine lipogenic gene expression. Data are represented as means ± SEM. 
*
p < 0.05 compared 
to chow-fed itgα1+/+ mice. §p < 0.05 compared to HF-fed itgα1+/+ mice. (n = 5-8/group). 
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Srebp-1c, Fas, Acc1, Scd1 and Elovl6 were increased in HF-fed itga1-/- mice. In contrast, 
expression of Dgat1 and Dgat2 genes, the genes responsible for catalyzing the final step in TG 
biosynthesis, were decreased in HF-fed itga1-/- mice (Figure 3.8D).   
Circulating free fatty acids (FFAs) are typically the major substrate for the accumulation 
of hepatic TGs (30). Thus we measured several markers of FFA metabolism in each mouse 
model. Basal 5-h fasting plasma FFAs were equal between the two genotypes (Figure 3.8A). 
Insulin suppressed plasma FFAs to a greater extent in HF-fed itga1-/- mice. Next we analyzed 
gene expression of several genes involved in the regulation of fatty acid metabolism including 
Cd36, Pparα, Pparγ and Cpt-1α (Figure 3.9B). Consistent with the finding that hepatic lipid 
accumulation was decreased in HF-fed itga1-/- mice, we found that gene expression for Cd36 
and Pparγ was decreased in HF-fed itga1-/- mice.      
To determine the contribution of mitochondrial fatty acid supported respiration to TG and 
DAG accumulation in both chow and HF-fed itgα1+/+ and itga1-/- mice we assessed 
mitochondrial oxygen consumption in mechanically permeabilized liver pieces. Mechanically 
permeabilized liver pieces were used in lieu of isolated mitochondria to ensure the cytoskeletal 
attachments are conserved and the mitochondria are not stressed during the functional 
measurements. ADP-stimulated (state 3) respiration in the presence of palmitoyl-carnitine and 
malate was increased in itga1-/- mice compared to itgα1+/+ mice regardless of diet (Figure 3.9D). 
There was no difference in glutamate/malate stimulated state 3 respiration (Figure 3.9C) or 
citrate synthase activity (data not shown) between groups. Thus the observed decrease in TG and 
DAG accumulation in HF-fed itga1-/- mice is linked to increased capacity for mitochondrial 
fatty acid supported respiration. 
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Figure 3.9 – Effect of integrin α1β1 on free fatty acid (FFA) metabolism. (A) Arterial non-
esterified free fatty acids (NEFAs) in the basal 5-h fasted state and during the insulin clamp. (B) 
Gene expression of several genes implicated in the regulation of fatty acid metabolism. mRNA 
was extracted from 5-h fasted livers and qPCR was used to determine gene expression (n = 5-
6/group). (C and D) High-resolution respirometry was performed on mechanically permeabilized 
liver pieces from 5-h fasted mice. Data are represented as means ± SEM. *p < 0.05 compared to 
chow-fed itgα1
+/+ 
mice and §p < 0.05 compared to HF-fed itgα1
+/+ 
mice. 
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Discussion 
Integrin α1β1 is a collagen binding integrin found on the hepatocyte (102). Results from 
these studies show that integrin α1 protein expression is increased in hepatocytes with HF 
feeding. The goal of this study was to determine whether increased expression of the integrin α1 
subunit with HF feeding would promote hepatic insulin action and protect against metabolic 
impairments in HF fed C57BL/6J mice. We found that integrin α1β1 signaling protects against 
diet-induced hepatic insulin resistance as it promotes hepatic insulin action. Insulin clamp studies 
showed that hepatic glucose production is completely resistant to suppression by an insulin 
stimulus in HF-fed itga1-/- mice and this is associated with decreased insulin signaling. Despite 
severe hepatic insulin resistance, HF-fed itga1-/- mice exhibit a 50% reduction in hepatic TG and 
DAG accumulation compared to their wild-type littermates. The reduction in hepatic lipids was 
associated with a combination of decreased FFA availability upon insulin stimulation, decreased 
gene expression of the fatty acid transporter Cd36 and increased mitochondrial fatty acid 
utilization.    
The hepatocyte is the most abundant cell type in the liver and is a major site of hepatic 
insulin action. Thus, it was important to determine the effects of HF feeding on integrin α1 
protein expression in isolated hepatocytes. Our studies show that integrin α1 protein expression 
is increased in hepatocytes isolated from wild-type mice after 16 weeks of HF feeding.   
To determine the role of integrin α1 in glucose and lipid metabolism, itgα1+/+ and itga1-/- 
mice were fed either a chow or HF-diet for 16 weeks. The whole body deletion of integrin α1 in 
HF fed mice resulted in a small decrease in fat mass (~ 8%). Glucose transported into the fat cell 
provides the three carbon backbone essential for the esterification of FFAs (186). Previous 
studies from our lab show that HF-fed itga1-/- mice have decreased insulin-stimulated adipose 
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tissue glucose uptake (178). Thus, it is reasonable to propose that this reduction in glucose 
uptake contributes to the small decrease in fat mass in the HF-fed itga1-/- mice.   
The measurement of basal 5-h fasting blood glucose and insulin revealed that fasting 
insulin was elevated in HF-fed itga1-/- mice indicating impaired glucose metabolism and 
potentially insulin resistance. Oral glucose tolerance was assessed in mice with an indwelling 
gastric catheter for glucose delivery and an arterial catheter for blood sampling. There was no 
difference in either the glycemic or insulin responses during the OGTT between genotypes. To 
determine whether the increase in integrin α1 protein expression improved hepatic insulin 
sensitivity in HF fed mice, insulin clamps were used to assess insulin action. Consistent with our 
previous report (178) HF-fed itga1-/- mice exhibited a lower glucose infusion rate (GIR) 
compared to HF-fed itgα1+/+ mice. Hepatic glucose production was suppressed by ~50% in HF-
fed itgα1+/+, while it was not suppressed in itga1-/- mice. This indicates a more severe hepatic 
insulin resistance in HF-fed itga1-/- mice. There was no difference in Rd during the insulin 
clamp. This indicates that the difference in the GIR during the insulin clamp is due to complete 
loss of hepatic insulin sensitivity and not decreased insulin-stimulated glucose disposal from 
tissues such as the skeletal muscle. The absence of skeletal muscle insulin resistance in HF-fed 
itga1-/- mice supports a previous observation from our laboratory showing that there is no 
difference in skeletal muscle insulin sensitivity between HF-fed itgα1+/+ and itga1-/- mice (178).   
Glucose tolerance is determined by several factors in addition to insulin resistance. These 
include glucose effectiveness (i.e. the ability of glucose to suppress endogenous glucose 
production and stimulate glucose uptake (187)) and insulin secretion and clearance. Since insulin 
concentrations were equal between genotypes during the OGTT, it is probable that impaired 
insulin action is offset by differences in glucose effectiveness. Moreover, arterial insulin 
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concentrations are similar in the two genotypes, but the insulin levels at the liver are unknown. 
The liver is perfused by hepatic portal venous blood, which is unobtainable in the mouse. It is 
well-accepted that arterial insulin does not reflect insulin in the portal vein.  Thus, one 
explanation for normal GTT, in the face of insulin resistance is different insulin concentrations at 
the liver. Overall, these studies highlight the value of considering both glucose tolerance and 
insulin action as distinct read outs when determining the metabolic phenotype of novel mouse 
models.   
The complete lack of suppression of hepatic glucose production during the insulin clamp 
in HF-fed itga1-/- mice was associated with decreased insulin-stimulated IRS1 and Akt 
activation followed by no insulin-mediated suppression of G6pc gene expression and increased 
insulin-mediated Pepck gene expression. This occurred in the absence of differences in insulin-
mediated Foxo1 phosphorylation at Ser
253
 in whole liver homogenate. There was also no 
difference in insulin receptor phosphorylation. This suggests that there may be some aspect of 
integrin α1β1 signaling that promotes hepatic insulin action downstream of the insulin receptor 
in HF-fed mice (142). To further investigate how the deletion of integrin α1 in HF-fed mice 
results in decreased IRS1 and Akt activation, we assessed activation of several signaling 
molecules in the MAPK signaling pathway including ERK1/2 and JNK1/2. Previous studies 
implicate a role for JNK activation in the development of hepatic insulin resistance by decreasing 
insulin-induced tyrosine phosphorylation IRS1 (188). In contrast, we found that activation of this 
pathway was downregulated in HF-fed itga1-/- mice compared to HF-fed itgα1+/+ mice 
indicating that the absence of integrin α1 dampens MAPK signaling despite hepatic insulin 
resistance and JNK activation is not responsible for the observed decrease in IRS1 Tyr 
phosphorylation in HF-fed itga1-/- mice.   
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There is considerable crosstalk between the insulin and integrin signaling cascades 
(62,142,176,177). A potential mediator of this crosstalk is the integrin specific signaling 
molecule, FAK. FAK has been implicated in the regulation of hepatic insulin signaling 
(144,146,152). Decreased FAK signaling is associated with decreased hepatic IRS1 and Akt 
phosphorylation (144). Furthermore, fa/fa rats treated with a TNF-α neutralizing agent exhibited 
increased hepatic FAK phosphorylation associated with decreased hepatic glucose output (152). 
In contrast to these studies, our findings showed that down regulation of FAK phosphorylation is 
not essential for the severe insulin resistance in insulin clamped HF-fed itga1-/- mice compared 
to their wild-type littermates. There was a tendency for increased FAK activation in the basal 5-h 
fasted itga1-/- mice; however this trend was equivalent regardless of diet. It is notable however, 
that we do see a striking decrease in FAK phosphorylation in livers from 5-h fasted HF-fed mice 
compared to chow-fed mice regardless of genotype. This suggests that HF feeding facilitates an 
integrin α1β1 independent inhibition of FAK activation. Although the hepatic insulin resistance 
seen in the HF-fed itga1-/- mice cannot be attributed to decreased FAK phosphorylation, this 
may be an independent mechanism whereby HF feeding decreases hepatic insulin action in wild-
type mice.  
To further elucidate the mechanisms of the severe hepatic insulin resistance in the HF-fed 
itga1-/- mice, we measured hepatic lipid accumulation in our mouse models. Hepatic TG 
accumulation, or its lipogenic metabolites, can decrease hepatic insulin action (29,51). 
Surprisingly, we found that HF-fed itga1-/- mice exhibit a 50% reduction in hepatic TG and 
DAG accumulation compared to their wild-type littermates. This data is important for several 
reasons. First, it suggests that integrin α1β1 promotes TG and DAG accumulation in the liver.  
Second, hepatic steatosis is dissociated from insulin resistance in HF-fed itga1-/- mice.  This 
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makes it a unique model of hepatic insulin resistance. It also supports other studies (28,56-58) 
that show that insulin resistance can be dissociated from lipid accumulation and can exist in the 
absence of increased TG and DAG.   
To identify a potential mechanism whereby HF-fed itga1-/- mice exhibit decreased TG 
and DAG accumulation, we examined indices of TG synthesis and breakdown in both the HF-
fed itgα1+/+ and itga1-/- mice. These include lipogenesis, VLDL secretion, circulating FFAs and 
mitochondrial fatty acid respiration (28-30). Results from the present studies show that 
expression of the lipogenic genes Srebp-1c, Fas, Acc1, Scd1 and Elovl6 were increased. This 
indicates that the decrease in hepatic lipid accumulation is independent of decreased expression 
of these key lipogenic genes. We propose this is the result of a feedback mechanism that exists to 
upregulate lipogenic pathways when hepatic lipid stores are low. This supports the notion that 
the liver promotes the incorporation of lipid metabolites into neutral lipid droplets to protect 
against the deleterious effects of a HF diet. TG synthesis is regulated by the step-limiting 
enzyme, diglyceride acyltransferase (DGAT). Contrary to the increase in genes involved in 
lipogenesis, we found that gene expression for two predominant isoforms of DGAT (Dgat1 and 
Dgat2) was decreased. This finding may explain, at least in part, why hepatic DAG and TG 
accumulation is decreased in HF-fed itga1-/- mice.  This conclusion is supported by previously 
published work from Chen et al. (189).  In this study, the global deletion of DGAT1 resulted in a 
decrease in hepatic DAG levels. To determine whether a critical substrate for the DGAT reaction 
was altered, we measured hepatic G3P levels. Our results indicate that G3P levels are increased 
in the livers of HF-fed itga1-/- mice (35.6 ± 4.7 and 48.4 ± 1.8 nmol/mg liver) suggesting that 
the observed decrease in lipid accumulation is independent of hepatic G3P levels.          
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The majority of liver TGs are derived from circulating FFAs (30,37). Here we show that 
HF-fed itga1-/- mice have decreased circulating FFAs compared to HF-fed itgα1+/+ mice during 
the insulin clamp. This indicates that insulin suppresses circulating FFAs to a greater extent in 
HF-fed itga1-/- mice suggesting that insulin-mediated lipolysis (i.e. the hydrolysis of 
triacylglycerol in adipocytes) is blunted and this may account for the decreased lipid 
accumulation.   
CD36 is key for FFA transport into the hepatocyte and CD36 expression is correlated 
with liver fat content (190,191). Our results show that liver Cd36 gene expression was in fact 
decreased in itga1-/- mice consistent with the reduction in lipid accumulation. Additionally, 
CD36 is a known transcriptional target of PPARγ (192). In further support of the decrease in 
Cd36 gene expression, our studies show that gene expression for Pparγ was also decreased.       
FFAs are esterified into TGs or oxidized by the mitochondria in the hepatocyte (193). 
When the supply of FFAs exceeds the amount the mitochondria can oxidize, hepatic fat 
accumulation occurs. To determine the contribution of the mitochondria to fatty acid utilization 
in the chow and HF-fed itgα1+/+ and itga1-/- mice, palmitoyl-carnitine/malate stimulated state 3 
respiration was measured in mechanically permeabilized liver pieces. Results show that 
palmitoyl-carnitine stimulated state 3 respiration is higher in itga1-/- mice regardless of diet. 
This suggests that hepatic mitochondria in itga1-/- mice have a greater capacity to utilize fatty 
acid substrates. Hepatic mitochondrial oxygen flux was not different in chow and HF-fed mice. 
This result is supported by a study from Satapati et al. that also showed no difference in hepatic 
mitochondrial palmitoyl-carnitine/malate supported state 3 respiration at 16 weeks of HF feeding 
in mice (194). The differences in mitochondrial respiration (i.e. fatty acid utilization by the 
mitochondria) occurred in the absence of differences in the expression of genes involved in the 
75 
 
regulation of fatty acid oxidation (i.e. Pparα and Cpt-1α). Overall the results show that the 
decrease in hepatic lipid accumulation in the HF-fed itga1-/- mice is due to regulation at multiple 
sites. Hepatic FFA availability and uptake of FFAs are decreased while FFA utilization by the 
mitochondria is increased.   
Here we introduce for the first time that integrin α1 is upregulated in hepatocytes as an 
important adaptive response to over nutrition and that this may protect against more severe 
insulin resistance. This novel concept is illustrated in Figure 3.10. In HF-fed wild-type mice, the 
combination of both insulin and integrin α1β1 signaling leads to IRS1 and Akt phosphorylation 
resulting in the partial suppression of hepatic glucose output. In contrast, when integrin α1 is 
absent, insulin-mediated IRS1 and Akt activation is decreased. This results in the complete 
absence of insulin-induced suppression of hepatic glucose production. Interestingly, the profound 
insulin resistance observed in HF-fed itga1-/- mice is not only independent of increased hepatic 
TG and DAG concentrations, it occurs in the presence of a striking decrease in these lipids.  This 
is attributed to alterations in free fatty acid metabolism. In HF-fed wild-type mice, circulating 
FFAs are taken up by the liver and utilized for the synthesis of DAG and TG.  In HF-fed itga1-/- 
mice, circulating FFAs are lower and those that are available within the hepatocyte are utilized to 
a greater extent by the mitochondria for mitochondrial respiration.   
The mouse model utilized in these studies was a whole-body deletion of the integrin α1 
subunit. The liver is a heterogeneous tissue comprised of many different cell types including, but 
not limited to, hepatocytes, sinusoidal lining cells, endothelial cells, stellate cells and Kupffer 
cells. The hepatocyte is the most abundant cell type, making up approximately 80% of the cells 
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Figure 3.10 – Model whereby the integrin α1β1 protects against severe hepatic insulin resistance 
while promoting TG accumulation. Integrin α1 protein expression increases when wild-type 
(WT) mice are fed a high fat diet. This leads to increased integrin α1β1 cell signaling upon 
collagen binding. Upon insulin stimulation, the combination of both insulin and integrin α1β1 
signaling leads to the phosphorylation and subsequent activation IRS1 and Akt. This results in 
the partial suppression of hepatic glucose output. Circulating free-fatty acids (FFAs) are taken up 
by the liver and utilized primarily for the synthesis of diglyceride (DAG) and triglyceride (TG) 
while some may be shunted towards the mitochondria for mitochondrial respiration.  In contrast, 
when integrin α1 null mice are fed a high fat diet and insulin levels are high, the absence of 
integrin signaling leads to decreased IRS1 and Akt activation. This results in no suppression of 
hepatic glucose output. Circulating FFAs are lower and the available FFAs are utilized primarily 
by the mitochondria for mitochondrial respiration. This results in decreased DAG and TG levels.  
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 in the liver, and is a major site of hepatic insulin action and lipid metabolism (60). Thus, it 
seems highly likely that the observed metabolic phenotype is a result of changes within the 
hepatocyte.  In summary, this study shows for the first time the novel role of integrin α1β1 in the 
regulation of hepatic glucose and lipid metabolism under conditions of over nutrition in vivo. 
Furthermore, the interaction of integrin and insulin signaling is critical in determining the scope 
and severity of insulin resistance.   
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Chapter IV 
 
 
INTEGRIN-LINKED KINASE IS A MAJOR CONTRIBUTOR TO HEPATIC INSULIN 
RESISTANCE IN HIGH FAT FED MICE 
 
Aims 
The results from Chapter III demonstrate that integrin α1 protein expression is 
upregulated in hepatocytes with HF feeding and this exerts a protective effect against the 
deleterious effects of a HF diet. The goal of Chapter IV was to determine whether integrin α1β1 
signaling through integrin-linked kinase (ILK) protects against the development of hepatic 
insulin resistance in high fat (HF) fed mice. In this chapter, mice with a hepatocyte-specific 
deletion of ILK were generated and the metabolic effects of ILK deletion were assessed in both 
chow and HF-fed mice. In this Chapter, I hypothesize that the hepatocyte-specific deletion of 
ILK would impair hepatic insulin action in HF-fed mice.    
 
Introduction 
The prevalence of metabolic syndrome and Type 2 diabetes (T2D) have increased 
dramatically in recent years (195).  Insulin resistance is a hallmark of metabolic syndrome and it 
precedes the development of T2D (1,2). The liver is integral to maintaining whole-body glucose 
homeostasis. Under normal conditions, insulin suppresses hepatic glucose production. In the 
insulin resistant state, insulin fails to suppress hepatic glucose production resulting in 
hyperglycemia. In addition to maintaining glucose homeostasis, insulin also promotes hepatic 
triglyceride (TG) synthesis and storage within the liver during nutrient overload. This results in 
increased hepatic lipid accumulation, liver damage and increases in extracellular matrix (ECM) 
proteins such as collagen (32,51,175).    
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Figure 4.1 – Scheme of the hypothesis presented in Chapter IV. In high fat fed wild-type mice, 
insulin binds to the insulin receptor and the combination of both integrin and insulin signaling, 
stimulates the phosphorylation of IRS1 and Akt through integrin-linked kinase (ILK). This 
results in the partial suppression of hepatic glucose output during an insulin clamp. In high fat 
fed integrin α1-null mice, there is no signal transduction through either integrin α1β1 or ILK. 
When insulin binds its receptor this leads to the partial phosphorylation of IRS1 and Akt and 
results in no suppression of hepatic glucose output during the insulin clamp.  
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Integrins provide physical links to the ECM and transmit signals to the intracellular space 
through protein-protein interactions and signaling events (62). They lack enzymatic activity; 
therefore signal transduction by integrins occurs through the recruitment of signaling and/or 
adaptor proteins to their cytoplasmic tails (127). One such protein is integrin-linked kinase 
(ILK). ILK is a highly conserved intracellular scaffolding protein located at focal adhesions. It 
interacts with the β1, β2 and β3-integrin cytoplasmic domains and numerous cytoskeleton-
associated proteins such as actin. Interestingly, ILK was originally identified as a kinase due to 
the significant sequence homology of the C-terminus to other Ser/Thr protein kinases (129). 
Since then, several lines of evidence have confirmed that ILK does not possess an active kinase 
domain and it is now classified as a bona fide pseudokinase (130,131). The pseudokinase domain 
of ILK is an essential domain for the recruitment of several adaptor proteins and signaling 
molecules including proteins involved in insulin action such as PKB/Akt, PDK1 and GSK-3β. 
Therefore although ILK lacks intrinsic kinase activity, it has been implicated in the regulation of 
numerous intracellular growth factor signaling cascades (135-137).  
ILK is a major mediator of integrin signaling and is a key regulator of ECM-cell 
interactions. Extensive research has been conducted on ILK signaling and function in tissue 
culture cell systems (127,196,197). However few studies have focused on the role of ILK in the 
liver and even fewer have focused on the role of hepatic ILK in vivo. ILK protein expression is 
increased in a rodent model of liver fibrosis (158). ILK has been shown to be involved in the 
regulation of matrix-induced hepatocyte differentiation in vitro and in vivo (159). Studies in mice 
have described a role for ILK in the regulation of liver ECM response to liver injury (159,198-
200). The genetic deletion of ILK from hepatocytes results in enhanced liver regeneration (198). 
ILK expression is upregulated during liver wound healing and has been shown to be involved in 
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the fibrotic response to liver injury. Collectively, these studies show that the interaction between 
hepatocytes and the ECM through ILK are critical for the liver regeneration and differentiation. 
Nonetheless, to date, no studies have investigated the role of ILK in the context of hepatic 
metabolic derangements that occurs as a result of HF feeding.  
Hepatic insulin resistance is associated with increased collagen. Integrin α1β1 is the only 
collagen binding integrin shown to be expressed on the hepatocyte. The results presented in 
Chapter III show that the whole-body deletion of integrin α1 leads to severe hepatic insulin 
resistance in mice fed a HF diet compared to controls. Integrins lack intrinsic catalytic activity 
therefore they are reliant on the recruitment of signaling and/or adaptor proteins to their 
cytoplasmic tails to facilitate signal transduction. Two main integrin signaling proteins are the 
cytoplasmic tyrosine kinase, FAK, and the scaffolding protein, ILK. Results from Chapter III 
demonstrate that differences in FAK activation are not responsible for the observed phenotype in 
HF fed integrin α1-null mice. Thus it was hypothesized that integrin α1β1 signals through ILK to 
protect against diet-induced hepatic insulin resistance (Figure 4.1).  
To test this hypothesis, mice with a hepatocyte-specific deletion and their wild-type 
littermates on a C57BL/6J background were generated and placed on either a chow or HF diet. 
Insulin sensitivity was assessed using the hyperinsulinemic-euglycemic (insulin) clamp. Contrary 
to the original hypothesis, here we show that the deletion of hepatocyte ILK results in the 
complete restoration of hepatic insulin sensitivity in HF-fed mice. This was evidenced by full 
insulin-mediated suppression of hepatic glucose production during the insulin clamp, increased 
insulin signaling and greater insulin-mediated suppression of gluconeogenic gene expression. 
There was no difference in the chow-fed mice between genotypes. The improvement in hepatic 
insulin action in HF-fed mice was associated with decreased hepatic lipid accumulation and 
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increased mitochondrial glucose oxidation. In summary, hepatic ILK deletion has no effect on 
insulin action in lean mice, but sensitizes the liver to insulin during the challenge of HF feeding.  
 
Experimental Design 
The global deletion of ILK is embryonic lethal due to defects in F-actin organization and 
epiblast polarity (160). Thus, mice with a hepatocyte-specific deletion of integrin-linked kinase 
(ILK) were used to determine the role of ILK in the regulation of hepatic insulin action in high 
fat (HF) fed mice. Mice carrying an ILK allele flanked by loxP sites (ILK
lox/lox
, kindly provided 
by Dr. Roy Zent) (161) were crossed to transgenic mice expressing Cre recombinase under the 
control of the albumin (Alb) promoter (purchased from Jackson Laboratory) to generate 
ILK
lox/lox
Albcre mice and wild-type littermates, ILK
lox/lox
 mice. Mice were fed either a standard 
chow diet (5.5% fat by weight; 5001 Purina Laboratory Rodent Diet) or HF diet (60% kcal from 
fat; F3282 BioServ) for 16 weeks. All studies were performed at 19 weeks of age. Insulin action 
was assessed using the insulin clamp combined with tracer techniques to determine sites of 
insulin resistance. See Chapter II for detailed methods. 
 
Results 
 
Components of the ILK-PINCH-parvin (IPP) complex are differentially expressed in 
hepatocytes with HF feeding 
HF-feeding can differentially regulate protein expression in hepatocytes. To determine 
whether the expression of different components of the IPP complex are effected by HF-feeding, 
western blot analysis was used to determine ILK, PINCH and α-parvin protein expression in 
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hepatocytes isolated from chow and HF-fed mice. The results from this study show that ILK 
protein expression is decreased and PINCH and α-parvin protein expression was increased in 
hepatocytes isolated from HF-fed mice compared to chow-fed mice (Figure 4.2).  
 
Adaptations to the genetic deletion of ILK from hepatocytes 
Mice expressing Cre-recombinase under the Albumin promoter (purchased from Jackson 
Laboratory) were crossed with ILK
lox/lox
 mice to generate mice with a hepatocyte specific 
deletion of ILK (ILK
lox/lox
Albcre) and wild-type littermates, ILK
lox/lox
 mice (161). Livers were 
perfused with collagenase to isolate liver cells and differential centrifugation was used to 
separate hepatocytes from nonparenchymal cells. The deletion of ILK in hepatocytes was 
confirmed in ILK
lox/lox
Albcre mice by performing western blot analysis (Figure 4.3B). ILK was 
highly expressed in whole liver lysate and in the nonparenchymal cellular fraction (Figure 4.3A 
and C). This is consistent with another study confirming the high expression of ILK in other cell 
types in the liver including endothelial cells, Kupffer cells, stellate cells and biliary cells (201).    
To determine the role of ILK in hepatic insulin action in vivo, ILK
lox/lox
 and ILK
lox/lox
Albcre mice 
were placed on either a chow or HF diet. HF feeding increased body weight and adiposity (Table 
4.1). There were no differences in body weight, adiposity or lean mass at 19 weeks of age 
between the genotypes on either a chow or HF diet.  
 
Hepatic insulin action is improved in HF ILK
lox/lox
Albcre mice 
Insulin action was assessed in ILK
lox/lox
 and ILK
lox/lox
Albcre mice on both a chow and HF 
diet using the hyperinsulinemic-euglycemic (insulin) clamp. During the insulin clamp, blood 
glucose was maintained between 130-140 mg/dL (Figure 4.4A and C). There was no difference 
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Figure 4.2 – Components of the Integrin-linked kinase (ILK)-PINCH-Parvin (IPP) complex are 
differentially expressed in hepatocytes isolated from high fat fed mice. (A) Western blot analysis 
in isolated hepatocytes. (B) Quantitative analysis of data from A. Integrated intensities were 
obtained by the Odyssey and Image J software. Protein expression was normalized to β-actin. 
Data are represented as means ± SEM; n = 5/group. *p < 0.05 chow vs. high fat fed. 
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Figure 4.3 – Integrin-linked kinase (ILK) is absent in hepatocytes isolated from ILKlox/loxAlbcre 
mice. Western blot analysis for ILK protein expression in (A) whole liver lysate, (B) hepatocytes 
and (C) nonparenchymal cells isolated from ILK
lox/lox
 and ILK
lox/lox
Albcre mice.  
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in the glucose infusion rate (GIR), endoRa or glucose utilization (Rd) (Figure 4.5A, B and C) 
during the insulin clamp between the chow fed ILK
lox/lox
 and chow fed ILK
lox/lox
Albcre mice. 
The GIR was increased in HF-fed ILK
lox/lox
Albcre mice by 50% compared to HF-fed ILK
lox/lox
 
mice (Figure 4.4D). Basal endogenous glucose production (endoRa) was not different between 
genotypes (Figure 4.5A and D). Suppression of endo Ra during the insulin clamp was attenuated 
in ILK
lox/lox 
mice by the HF diet; while suppression of endo Ra was fully restored in 
ILK
lox/lox
Albcre mice demonstrating complete restoration of hepatic insulin sensitivity (Figure 
4.5D).  There was no difference in Rd during the insulin clamp (Figure 4.5B and E). Basal 5-h 
fasted plasma insulin values were not different between the genotypes and plasma insulin was 
raised during the insulin clamp (Figure 4.5C and F).  
 ILK has been shown to interact with several modulators of the insulin signaling cascade 
such as Akt (202). To determine whether the hepatocyte specific deletion of ILK affected insulin 
signaling, several markers of insulin signaling were assessed in basal 5-h fasted and insulin 
stimulated livers from HF-fed ILK
lox/lox
 and ILK
lox/lox
Albcre mice using western blot analysis 
(Figure 4.6A, B, D and E). IRS1, Akt and FAK phosphorylation were all increased in the liver 
with an insulin stimulus regardless of genotype. There was a slight increase in the 
phosphorylation of IRS1 at Y612 in the basal 5-h fasted ILK
lox/lox
Albcre mice (Figure 4.6A and 
D). Consistent with the hepatic glucose flux measurements, Akt phosphorylation at S473 was 
elevated in the HF-fed ILK
lox/lox
Albcre mice with an insulin stimulus (Figure 4.6A and C). To 
further determine the role of ILK in insulin signaling within the liver, an antibody microarray 
was used to identify several proteins that were upregulated or downregulated in insulin-
stimulated livers from HF-fed ILK
lox/lox
Albcre mice compared to HF-fed ILK
lox/lox
 mice. These 
proteins are represented in Table 4.2. The upregulated proteins in the livers from HF-fed  
87 
 
Table 4.1 
Metabolic characteristics of mice with a hepatocyte-specific deletion of ILK (ILK
lox/lox
Albcre) 
and wild-type mice (ILK
lox/lox
) fed either a chow or high fat diet. 
 
 
 Chow High Fat 
 ILK
lox/lox
 ILK
lox/lox
Albcre ILK
lox/lox
 ILK
lox/lox
Albcre 
N 8 8 5 6 
Weight (g) 29.5 ± 1.2      29.7 ± 1.1 41.3 ± 2.1* 38.0 ± 1.8† 
Adiposity (%) 10.6 ± 1.8        7.4 ± 0.42  31.8 ± 2.0      32.3 ± 3.1 
Absolute lean mass (g) 20.8 ± 0.7      22.6 ± 0.6  26.0 ± 0.9      24.1 ± 0.9 
Age at study (wks) 19 19 19 19 
Duration on diet (wks) 16 16 16 16 
Blood glucose (mg/dL) 
    
         Basal 136 ± 4 136 ± 3   146 ± 15        129 ± 7 
         Clamp 135 ± 2 140 ± 4   135 ± 2        130 ± 4 
 
 
Fasting and insulin clamp characteristics of wild-type (ILK
lox/lox
) and ILK
lox/lox
Albcre mice fed 
either a chow or high fat diet. Body weight, body composition and fasting blood glucose were 
determined in basal 5-h fasted mice. Data are represented as means ± SEM. *p < 0.05 compared 
to chow fed ILK
lox/lox
 mice. 
†
p < 0.05 compared to chow fed ILK
lox/lox
Albcre mice.  
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Figure 4.4 – Whole-body insulin sensitivity is greater in high fat (HF) fed ILKlox/loxAlbcre mice 
compared to controls. Arterial glucose (A and C) and the glucose infusion rate (B and D) were 
measured during the hyperinsulinemic-euglycemic (insulin) clamp (n = 5-8/group). Mice were 
fasted for 5-h prior to the start of the insulin clamp. Blood glucose was maintained between 130-
140 mg/dL during the steady state (80-120 min). Glucose (50%) was infused to maintain 
euglycemia. Data are represented as means ± SEM; n = 5-6/group. *p < 0.1.  
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Figure 4.5 – Hepatic insulin sensitivity is improved in HF-fed ILKlox/loxAlbcre mice. 
Endogenous glucose production (endoRa)(A and D) and whole-body disappearance (Rd)(B and 
E) were determined during the steady state period of the insulin clamp (n = 5-8/group). Arterial 
insulin (C and F) was determined in the basal 5-h fasted state and during the insulin clamp. Data 
are represented at means ± SEM. *p < 0.05 compared to HF ILK
lox/lox
Albcre. 
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Figure 4.6 – Hepatic insulin action is increased in high fat (HF) fed ILKlox/loxAlbcre mice. 
Western blot analysis was performed on liver homogenates from basal 5-h fasted and 5-h fasted 
insulin clamped mice (A)( (n = 4/group). (B, D and E) Quantitative analysis of western blots. (C, 
E and G) Fold increase of insulin-stimulated activation was calculated relative to wild-type 
(ILK
lox/lox
) mice. Integrated intensities were obtained by the odyssey and Image J software. (F) 
mRNA was extracted from both basal 5-h fasted and 5-h fasted insulin clamped livers. qPCR 
was performed to determine gene expression of the gluconeogenic genes G6pc and Pepck. Data 
are represented at means ± SEM. *p < 0.05. 
∆
p < 0.05 compared to 5-h fasted HF ILK
lox/lox
 mice.  
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Table 4.2 
Protein microarray data from high fat fed ILK
lox/lox
 and ILK
lox/lox
Albcre mice.  
 
Target Protein Name 
 
Phospho Site  Full Target Protein Name Z-ratio  
Rb S807 Retinoblastoma-associated protein 1 3.79 
S6K S424 p70 ribosomal protein-serine S6 kinase 2.46 
Fyn Pan-specific Fyn proto-oncogene-encoded protein-tyrosine kinase 2.39 
PKBb (Akt2) Pan-specific Protein-serine kinase B beta 2.37 
TBK1 Pan-specific Serine/threonine-protein kinase TBK1 2.35 
Shc1 Y349 SH2 domain-containing transforming protein 1 2.16 
PKBb (Akt2) Pan-specific Protein-serine kinase B beta 2.15 
Syk Y323 Spleen protein-tyrosine kinase 2.14 
S6K S411 p70 ribosomal protein-serine S6 kinase 2.14 
MST1 Pan-specific Mammalian STE20-like protein-serine kinase 1 (KRS2) 2.12 
Myc S373 Myc proto-oncogene protein 2.08 
PKCh Pan-specific Protein kinase C eta type 1.97 
Gab1 Y627 GRB2-associated binder 1 1.94 
Raf1 Pan-specific Raf1 proto-oncogene-encoded protein-serine kinase 1.92 
JNK1/2/3 Pan-specific Jun N-terminus protein-serine kinase  (SAPK) 1/2/3 1.83 
HDAC5 S498 Histone deacetylase 5 1.83 
GSK3a Pan-specific Glycogen synthase-serine kinase 3 alpha 1.80 
MEK7 (MAP2K7) Pan-specific MAPK/ERK protein-serine kinase 7 (MKK7) 1.77 
DDIT3(CHOP) Pan-specific DNA damage-inducible transcript 3 protein 1.77 
PAK2 Pan-specific p21-activated kinase 2 (gamma) (serine/threonine-protein kinase 2) 1.75 
Smac/DIABLO Pan-specific Second mitochondria-derived activator of caspase 1.71 
IkBa Pan-specific Inhibitor of NF-kappa-B alpha (MAD3) 1.69 
GroEL Pan-specific GroEL homolog (may correspond to Hsp60) 1.68 
FKHR S256 Forkhead box protein O1 1.64 
MEK5 (MAP2K5) Pan-specific MAPK/ERK protein-serine kinase 5 (MKK5) 1.60 
JAK1 Pan-specific Janus protein-tyrosine kinase 1 1.57 
GATA1 S142 Erythroid transcription factor 1.56 
JNK2 (MAPK9) Pan-specific Jun N-terminus protein-serine kinase (SAPK) 2 1.53 
Tubulin Pan-specific Tubulin -1.51 
MEK4 (MAP2K4) S257+T261 MAPK/ERK protein-serine kinase 4 (MKK4) -1.52 
Bax Pan-specific Apoptosis regulator Bcl2-associated X protein -1.53 
4G10 pTyr 4G10 -1.58 
Catenin b1 Pan-specific Catenin (cadherin-associated protein) beta 1 -1.63 
PKA Cb S339 cAMP-dependent protein-serine kinase catalytic subunit beta -1.65 
MLK3 T277+S281 Mixed-lineage protein-serine kinase 3 -1.73 
MEK3/6 (MAP2K3/6) S218/S207 MAPK/ERK protein-serine kinase 3/6 (MKK3/6) -1.74 
BLNK Y84 B-cell linker protein -1.85 
WIP1 Pan-specific Protein phosphatase 1D -1.90 
ATF2 T69 + T71 Activating transcription factor 2 (CRE-BP1) -2.58 
Paxillin 1 Y118 Paxillin 1 -3.01 
 
Protein and phosphoprotein expression in livers from 5-h fasted high fat fed ILK
lox/lox
Albcre 
mice compared to ILK
lox/lox
 mice. A Z ratio of ± 1.2 to 1.5 is considered significant.   
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ILK
lox/lox
Albcre mice included Akt2, TBK1, and GSK3a as well as several proteins in the MAPK 
signaling cascade such as Raf1, MAP2K7, MAP2K5 and MAPK9. In support of the improved 
insulin sensitivity in HF-fed ILK
lox/lox
Albcre mice, FoxO1 phosphorylation at S256 was 
increased. 
To determine the effect of ILK on hepatic gluconeogenic gene expression in the HF-fed 
state, qPCR was used to determine gene expression of glucose-6-phosphatase (G6pc) and 
phosphoenolpyruvate carboxylase (Pepck) in the livers from basal 5-h fasted and insulin clamped 
mice (Figure 4.6H). G6pc and Pepck gene expression were increased in 5-h fasted HF-fed 
ILK
lox/lox
Albcre mice. There was no suppression of either G6pc or Pepck gene expression in the 
HF-fed ILK
lox/lox
 mice. In contrast, and in support of the insulin clamp data and Akt signaling, 
G6pc and Pepck expression were greatly suppressed with an insulin stimulus in HF-fed 
ILK
lox/lox
Albcre mice.   
Liver glycogen was determined in basal 5-h fasted and insulin clamped livers from HF-
fed ILK
lox/lox
 and ILK
lox/lox
Albcre mice. Fasting glycogen levels were increased in HF-fed 
ILK
lox/lox
Albcre mice (Figure 4.7A). Insulin stimulated the accumulation of glycogen in the 
livers of insulin clamped HF-fed ILK
lox/lox
 mice; however this accumulation was blunted in the 
HF-fed ILK
lox/lox
Albcre mice. There was no difference in the glycogen synthetic rate between the 
genotypes during the insulin clamp (Figure 4.7B). Mitochondrial dysfunction is associated with 
the development of diet-induced hepatic insulin resistance (203). To test the hypothesis that 
mitochondrial function was improved in the HF-fed ILK
lox/lox
Albcre mice, high-resolution 
respirometry was used to determine mitochondrial function in isolated mitochondria (Figure 
4.8A and B). State 2 respiration with the substrates glutamate and malate was not different 
between the genotypes. Consistent with our hypothesis, glutamate/malate stimulated state 3  
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Figure 4.7 – Effect of hepatocyte ILK deletion on liver glycogen metabolism. Liver glycogen 
(A) was assessed in livers from basal 5-h fasted mice and in livers excised immediately after the 
insulin clamp. Liver insulin-stimulated glycogen synthetic rate (B) was determined in livers 
excised immediately after the insulin clamp. Data are represented at means ± SEM. ∆p < 0.05 
compared to 5-h fasted HF ILK
lox/lox
 mice.
  §
p < 0.05 compared to insulin clamped ILK
lox/lox
 mice. 
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Figure 4.8 – Complex I supported mitochondrial respiration is higher in high fat (HF) fed 
ILK
lox/lox
Albcre mice. High-resolution respirometry (A) was performed on mitochondria isolated 
from livers of 5-h fasted mice. (B) The respiratory control ratio (RCR) was determined as  
state 3 /state 2 respiration. Data are represented at means ± SEM. *p < 0.05. 
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respiration was increased in ILK
lox/lox
Albcre mice. There was no difference in the respiratory 
control ratio (RCR) between the groups (Figure 4.8B).    
 
Hepatic triglyceride content was decreased in mice with a genetic deletion of ILK 
HF feeding leads to the development of fatty liver and hepatic insulin resistance (51). To test the 
hypothesis that improved hepatic insulin action in HF-fed ILK
lox/lox
Albcre mice was associated 
with decreased triglyceride (TG) accumulation; several markers of lipid metabolism were 
measured. Hepatic triglyceride (TG) content was decreased in livers from basal 5-h fasted HF-
fed ILK
lox/lox
Albcre mice (Figure 4.9A). There was no difference in circulating basal 5-h fasted 
plasma TGs (Figure 4.9B). Lipogenic gene expression was determined using qPCR (Figure 
4.8C). Despite decreased TG accumulation, gene expression for the lipogenic genes Srebp-1c, 
Fas, Acc1, Dgat1 and Dgat2 were increased. Circulating free fatty acids (FFAs) are the main 
substrate for the synthesis and accumulation of hepatic TGs (30). In support of decreased TG 
content, circulating FFAs were decreased in HF-fed ILK
lox/lox
Albcre mice in both the basal 5-h 
fasted and insulin clamped states (Figure 4.9D). There was no difference in the % suppression 
between the genotypes. To determine the contribution of mitochondrial fatty acid supported 
respiration to the observed decrease in hepatic TGs, mitochondrial function was determined in 
isolated mitochondria using the fatty acid substrates palmitoyl-carnitine and malate (Figure 
4.9E). There was no difference in either state 2 or state 3 respiration between the genotypes or 
RCR (Figure 4.9F). 
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Figure 4.9 – Integrin-linked kinase (ILK) promotes hepatic lipid accumulation in high fat (HF) 
fed mice. Liver triglyceride content (A) was determined in livers from 5-h fasted mice. (B) 
Circulating plasma triglycerides in basal 5-h fasted mice. High-resolution respirometry (D) was 
performed on isolated mitochondria from livers of 5-h fasted mice. (C) mRNA was extracted 
from basal 5-h fasted livers and qPCR was used to determine gene expression of several 
lipogenic genes. (D) Arterial non-esterified free fatty acids (NEFAs) in basal 5-h fasted and 
insulin clamped mice. High-resolution respirometry (E) and respiratory control ratio (RCR) (F) 
from mitochondria isolated from livers of 5-h fasted mice. Data are represented at means ± SEM. 
*p < 0.05 compared to HF ILK
lox/lox
Albcre. 
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Discussion 
Hepatic insulin resistance is associated with increased collagen. Integrin α1β1 is the only 
collagen binding integrin expressed on the hepatocyte. Integrins lack intrinsic catalytic activity 
therefore they rely on associated kinases and scaffolding proteins to transduce signals from the 
ECM to the inside of the cell. This suggests that the ECM may contribute to the pathogenesis of 
hepatic insulin resistance through integrin signaling.  
The goal of this study was to determine whether integrin α1β1 signals through ILK to 
promote hepatic insulin action in HF fed mice. ILK is a major integrin signaling protein and 
facilitates communication from the ECM to the intracellular space. To eliminate this key effector 
of ECM-cell communication, we generated mice with a hepatocyte-specific deletion 
(ILK
lox/lox
Albcre mice) and their wild-type littermates (ILK
lox/lox
 mice) on a C57BL/6J 
background. The mice were fed either a chow or HF diet and hepatic glucose and lipid 
metabolism were assessed in vivo. Contrary to our hypothesis, here we show for the first time 
that the selective deletion of hepatic ILK in vivo results in the complete restoration of hepatic 
insulin sensitivity in HF-fed, but not chow fed, C57BL/6J mice. The increase in insulin action in 
HF-fed mice corresponds to changes in the activation of key signaling pathways, a greater 
capacity for hepatic mitochondrial glucose oxidation and decreased hepatic lipid accumulation. 
Hepatocytes are the most abundant cell type in the liver and a major site of hepatic 
insulin action and lipid metabolism (28). Thus, ILK
lox/lox
Albcre mice were generated to 
determine the metabolic effects of hepatic ILK deletion. Our data illustrate that ILK was 
selectively deleted from hepatocytes in the ILK
lox/lox
Albcre mice and not from the 
nonparenchymal cells of the liver. This occurred despite high expression of ILK protein in 
lysates prepared from the whole liver. The liver is composed of several different cell types 
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including stellate cells, Kupffer cells, and endothelial cells. This suggests that ILK is highly 
expressed in the nonparenchymal cells of the liver and may explain why ILK is still so highly 
expressed in lysates from whole livers. Our study is consistent with other studies reporting high 
expression of ILK in stellate cells and other hepatic cell types (158,201). 
ILK protein expression was determined in hepatocytes isolated from chow and HF-fed 
mice. Here we show that ILK protein expression is decreased in hepatocytes isolated from HF-
fed mice. In light of this finding, we propose that ILK protein expression is downregulated 
during times of over nutrition as mechanism to decrease integrin signaling and protect the 
hepatocyte against the deleterious effects of a HF-diet. The precise regulation of ILK expression 
is still unknown.    
Hepatic insulin resistance is characterized by increased hepatic glucose output despite 
high levels of circulating insulin. In our studies, the hyperinsulinemic-euglycemic (insulin) 
clamp was used to assess insulin action to determine the role of ILK in hepatic insulin action in 
vivo. Here we show that the glucose infusion rate (GIR) was increased in HF-fed ILK
lox/lox
Albcre 
mice by 50% compared to HF-fed ILK
lox/lox 
mice. There was no difference in the glucose 
infusion rate (GIR) or endoRa in chow mice during the insulin clamp. In HF-fed mice, basal 
endogenous glucose production (endoRa) was not different between genotypes. The insulin-
mediated suppression of endo Ra during the insulin clamp was attenuated in ILK
lox/lox 
mice by the 
HF diet, while suppression of endo Ra was fully restored in HF-fed ILK
lox/lox
Albcre mice. This 
demonstrates the complete restoration of hepatic insulin sensitivity in HF-fed ILK
lox/lox
Albcre 
mice. There was no difference in glucose utilization (Rd) during the insulin clamp indicating that 
the difference in GIR was solely attributed to differences in hepatic, and not peripheral, insulin 
action between the genotypes.  
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Mitochondrial dysfunction is a characteristic of the insulin resistant liver (203,204). In 
our study, we found that the increase in hepatic insulin sensitivity in HF-fed ILK
lox/lox
Albcre 
mice was associated with increased glutamate/malate stimulated state 3 respiration. Our data 
suggests that ILK decreases complex I based mitochondrial respiration in the presence of 
increased dietary lipids as a result of HF feeding. This is the first study to establish a role for ILK 
in the regulation of hepatic mitochondrial function.    
ILK has been implicated in the regulation of both integrin and growth factor signaling 
(136,153,205). For some time, it was postulated that ILK was a Ser/Thr kinase capable of 
directly phosphorylating Akt and GSK3β (129,137). An original study showed that purified ILK 
from mammalian cell extracts resulted in Akt phosphorylation (137). The overexpression of ILK 
in 3T3 cells resulted in increased phosphorylation of Akt and GSK-3β while Akt Ser473 
phosphorylation was diminished in cells transfected with kinase-deficient ILK (153). Moreover, 
the selective inhibition of ILK by siRNA reduced hepatic Akt phosphorylation in rats (158). 
Collectively, this led to the notion that ILK regulates Akt and GSK3β activation in vitro and in 
vivo. This has since been refuted. It is currently recognized that ILK is an adaptor protein that is 
part of a multiprotein complex that recruits kinases and promotes the phosphorylation of Akt and 
GSK3β through an indirect mechanism (136,205). However, no studies to date have addressed 
the role of ILK in the phosphorylation of hepatic Akt, or other key insulin signaling molecules 
such as IRS1, after a prolonged insulin stimulus in vivo. Here we show that there is no difference 
in the levels of Akt Ser473 phosphorylation between HF-fed ILK
lox/lox
 and ILK
lox/lox
Albcre in the 
basal 5h fasted state. In support of the insulin clamp data, insulin-mediated phosphorylation of 
Akt Ser473 was enhanced in HF-fed ILK
lox/lox
Albcre mice. This finding is supported by a study 
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showing that treatment of ILK deficient cells with insulin resulted in the robust phosphorylation 
of Akt at Ser473 and Thr308 (160).  
Focal adhesion kinase (FAK) is an integrin-associated cytoplasmic tyrosine kinase 
implicated in the regulation of hepatic insulin signaling (144,146,149). Thus we assessed FAK 
phosphorylation in livers from both basal 5h fasted and insulin clamped mice. Here we show that 
FAK Y397 phosphorylation is increased in the liver after an insulin clamp. This is consistent 
with other studies showing that insulin stimulates hepatic FAK phosphorylation (125,149).  
Integrin engagement has been shown to stimulate IRS1 activation (142). In our studies 
we show that IRS1 phosphorylation was increased in the basal 5h fasted state in HF-fed 
ILK
lox/lox
Albcre mice compared to HF-fed ILK
lox/lox
 mice. However, there was no difference in 
the fold increase in phosphorylated IRS1 between the genotypes. This indicates that the deletion 
of hepatic ILK improves insulin signaling downstream of IRS1 in insulin clamped livers. The 
increase in hepatic insulin signaling in HF-fed ILK
lox/lox
Albcre mice led to greater insulin-
mediated suppression of the gluconeogenic genes G6pc and Pepck. Collectively, our data show 
that hepatocyte ILK deletion improves hepatic insulin action during the challenge of HF feeding. 
Hepatic insulin resistance is associated with elevated hepatic lipid accumulation (51). 
Three days of HF feeding in mice results in a 3-fold increase in hepatic triglyceride (TG) 
accumulation and decreased suppression of hepatic glucose production during an insulin clamp 
(51). Here we show that hepatic TG accumulation is decreased in HF-fed ILK
lox/lox
Albcre mice 
compared to HF-fed ILK
lox/lox
 mice. A large fraction of liver TGs are derived from circulating 
free fatty acids (FFAs) (30,37), thus we measured circulating FFAs in our study. In accordance 
with decreased TG accumulation, circulating FFAs were decreased in both the basal 5h fasted 
state and during the insulin clamp in the HF-fed ILK
lox/lox
Albcre mice compared to HF-fed 
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ILK
lox/lox
 mice. There was no difference in the percent suppression with an insulin stimulus 
between the genotypes. It is important to note that the decrease in liver TGs in HF-fed 
ILK
lox/lox
Albcre mice occurred in the presence of increased gene expression for the lipogenic 
genes Srebp1c, Fas, Acc1, Dgat1 and Dgat2. This is in accordance with the studies in Chapter III 
where we reported that hepatic TG accumulation is reduced in HF-fed integrin α1 null mice 
despite increased lipogenic gene expression. We propose this is attributed to a feedback 
mechanism that upregulates lipogenic pathways when hepatic lipid stores are low. Collectively, 
these studies show that ILK promotes hepatic lipid accumulation via decreased availability of 
circulating FFAs in HF-fed mice.  
In summary, we demonstrate for the first time that hepatic ILK desensitizes the liver to 
insulin during the challenge of HF feeding and promotes hepatic lipid accumulation in vivo 
(Figure 4.10). The selective deletion of ILK from hepatocytes leads to a marked improvement in 
hepatic insulin action in HF-fed, but not chow fed, mice. This improvement was associated with 
increased insulin signaling, a greater capacity for hepatic mitochondrial glucose oxidation and 
decreased hepatic lipid accumulation. This study further emphasizes the importance of the ECM 
and integrin signaling in hepatic insulin action and lipid metabolism in HF-fed mice. 
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Figure 4.10 – Model whereby the hepatocyte-specific deletion of ILK facilitates insulin action 
and decreases lipid accumulation in the liver. Upon insulin stimulation, the combination of both 
insulin and integrin signaling through ILK leads to the phosphorylation and subsequent 
activation Akt. This results in the partial suppression of hepatic glucose output. Circulating free-
fatty acids (FFAs) are taken up by the liver and utilized for the synthesis of triglycerides (TG).  
In contrast, when ILK is absent and insulin levels are high, the absence of integrin signaling 
through ILK leads to increased Akt activation. This results in the full suppression of hepatic 
glucose output. Circulating FFAs are lower and this results in decreased hepatic TG levels.  
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Chapter V 
 
 
SUMMARY AND FUTURE DIRECTIONS 
 
The data presented within the Dissertation provide the first demonstration that integrins 
contribute to the regulation of hepatic insulin action and lipid metabolism in HF fed mice. The 
hepatocellular mechanisms of insulin resistance and lipid accumulation in the diet-induced obese 
mouse model have been characterized. The studies described herein add to the present 
understanding of insulin resistance by bridging hepatocyte metabolism and the ECM through 
plasma membrane associated integrin receptors. In Chapter III, I show that the integrin α1 
subunit is upregulated in hepatocytes during times of nutritional overload and this exerts a 
protective effect against the development of diet-induced hepatic insulin resistance while 
promoting lipid accumulation. In Chapter IV, I show that a downstream integrin signaling 
molecule, ILK, is also involved in the regulation of hepatic insulin action and lipid accumulation. 
The association between integrins and insulin signaling has not been well-studied. The studies in 
the Dissertation are amongst the first to demonstrate a mechanistic link between integrins and 
hepatic insulin action in vivo.  The results from these studies open new avenues for investigation 
in a novel area of metabolic research and identify innovative therapeutic targets to treat the 
underlying insulin resistance associated with Type 2 diabetes.  
The ECM is a dynamic structure that is constantly changing and remodeling during times 
of injury and repair (72). Results from these studies demonstrate that the liver ECM expands 
with HF feeding. This was evidenced by increased gene expression for several collagen chains in 
addition to increased hydroxyproline content in livers from HF fed mice compared to chow fed 
mice. The ECM communicates with cells through integrins. Integrins are unique as they 
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transduce signals from the ECM to the inside of the cell. Pathological states are associated with 
ECM remodeling and changes in integrin expression. The Dissertation studies are the first to 
describe changes in protein expression of an integrin and downstream integrin signaling proteins 
in hepatocytes from wild-type C57BL/6J HF-fed mice compared to chow-fed littermates. 
Collectively, the results in Chapter III show that integrin α1 protein expression is upregulated in 
hepatocytes with HF feeding, while the results in Chapter IV show that ILK protein expression is 
downregulated in hepatocytes with HF feeding. This indicates that the expression of hepatic 
integrins and integrin signaling proteins fluctuate as an adaptation to over nutrition, but that the 
directionality is specific.  
Cell-matrix adhesions through integrins are critical for normal liver function. They are 
responsible for many cellular processes including hepatocyte survival and differentiation. 
Several studies have described a role for integrins in the regulation of insulin signaling in 
adipocytes (142,176) and a large majority of these studies utilized a variety of tissue culture cell 
systems. To date, only two studies have assessed the contribution of integrins to insulin action in 
vivo (177,178). The focus of both of these studies was on the regulation of skeletal muscle 
glucose uptake by integrins. Yet, prior to the studies described herein, the mechanistic 
contribution of integrins to hepatic insulin action in vivo had never been assessed. In the 
Dissertation studies, two integrin mouse models were utilized to establish a role for integrins in 
hepatic insulin action in vivo. These were the integrin α1-null mouse model and mice with a 
hepatocyte-specific deletion of ILK. Each model provided valuable insight into the regulation of 
hepatic insulin action by integrins.  
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The studies described in Chapter III demonstrate that integrin α1-null mice exhibit severe 
hepatic insulin resistance when fed a HF diet. This is evidenced by the absence of a suppressive 
effect of insulin on hepatic glucose production during an insulin clamp compared to a 50% 
suppression in HF-fed wild-type littermates. The lack of suppression of hepatic glucose 
production was accompanied by decreased IRS1 and Akt phosphorylation indicating that integrin 
α1β1 facilitates insulin signaling and promotes hepatic insulin action.  
Integrins transduce signals to the inside of the cell through scaffolding proteins and 
downstream kinases (92). FAK and ILK are two prominent proteins described to facilitate 
integrin signal transduction. Several studies have established a role for FAK in the regulation of 
insulin signaling, thus it was hypothesized that integrin α1β1 promotes insulin action through 
FAK. To test this hypothesis, FAK phosphorylation was assessed in livers from HF fed integrin 
α1-null mice and their wild-type littermates. There was no difference in FAK phosphorylation 
between the genotypes in livers from either 5-h fasted or insulin-clamped mice. This strongly 
suggests that FAK activation was not responsible for the observed phenotype. In an attempt to 
test the hypothesis that α1β1 promotes hepatic insulin action in HF fed mice through a 
mechanism that requires ILK, mice with a hepatocyte-specific deletion of ILK were studied. The 
hypothesis was not correct. The results in Chapter IV show that the deletion of ILK from the 
hepatocyte actually improves hepatic insulin action in HF fed mice, suggesting that ILK 
contributes to diet-induced hepatic insulin resistance. 
These opposing effects of the two gene deletions on hepatic glucose production 
emphasize the complexity of the integrin signaling system. The integrin α1β1 studies described 
in Chapter III were conducted on mice with a whole-body deletion of the integrin α1 subunit. In 
contrast, the studies in Chapter IV were performed using mice with a hepatocyte-specific 
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deletion of ILK. The liver is a heterogeneous tissue comprised of several different cell types 
including hepatocytes, endothelial lining cells, Kupffer cells, and stellate cells. The hepatocyte is 
the major cell type involved in the regulation of hepatic insulin action. Nonetheless, other cell 
types such as Kupffer cells have also been shown to contribute to the pathogenesis of diet-
induced hepatic insulin resistance. For example, the depletion of Kupffer cells in male Wistar 
rats fed either a high sucrose or HF diet exhibit improved hepatic insulin sensitivity (206). Thus 
the ILK studies in Chapter IV can be isolated to insulin action within the hepatocyte, while the 
severe insulin resistance observed in the HF fed integrin α1-null mice described in Chapter III 
could be attributed to a combination of hepatic and extrahepatic effects.  
Moreover, there are 2 integrins known to be expressed on the hepatocyte, integrin α1β1 
and integrin α5β1. The whole-body deletion of integrin α1 eliminated hepatocellular integrin 
α1β1 signaling; however integrin α5β1 signaling remained intact. ILK interacts with several 
different integrin beta subunits including β1, β2 and β3. Integrin β1 is the only β integrin subunit 
known to interact with ILK that is expressed on hepatocytes (102). Integrin β2 is expressed on 
lymphocytes and while integrin β3 is highly expressed in the liver, no information exists 
regarding the expression of integrin β3 in hepatocytes. In integrin α1-null mice, integrin α1β1 is 
no longer able to signal, however integrin α5β1 is still present in hepatocytes and can signal 
through ILK. Hence, it is plausible that in the absence of integrin α1β1, integrin α5β1 is 
signaling through ILK and this promotes the development of severe hepatic insulin resistance in 
the presence of nutrient overload. This is depicted in Figure 5.1. It is also possible that there is 
some unidentified integrin α1 subunit binding partner that is modulating the protective effect 
observed in Chapter III. This unidentified binding partner could be identified experimentally in 
future studies via immunoprecipitation, SILAC and/or the yeast two-hybrid system.   
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Figure 5.1 – Proposed model whereby integrins regulate hepatic glucose and lipid metabolism in 
high fat fed mice. Upon insulin stimulation, integrin signaling through integrin α1β1 and ILK 
results in improved insulin action and decreased hepatic glucose output. In the absence of 
integrin α1β1 and in the presence of insulin, signaling through integrin α5β1 and ILK results in 
impaired insulin action and increased hepatic glucose output. Moreover, integrin signaling 
through integrins α1β1 and α5β1 and ILK results in hepatic lipid accumulation.   
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The studies conducted in Chapter III are noteworthy as they serve to refine what is 
currently known about the insulin resistant liver. Most strikingly, the severe hepatic insulin 
resistance observed in the integrin α1-null mouse model was present in the absence of TG and 
DAG accumulation. Not only were the hepatic lipids reduced, they were actually normalized to 
chow fed levels. Prior to this study, several lines of research (29,51-53) concluded that hepatic 
lipid accumulation directly causes hepatic insulin resistance. The results of the integrin α1β1 
studies indicate that hepatic insulin resistance can be completely dissociated from lipid 
accumulation.  
The severe hepatic insulin resistance observed in the HF fed integrin α1-null mice also 
occurred in the absence of differences in glucose tolerance. The liver is a major insulin sensitive 
organ and defects in liver insulin action contribute to the dysregulation of glucose homeostasis. 
Insulin resistance is one of several factors that can influence glucose tolerance. It is often 
assumed that in rodent models, impaired glucose tolerance combined with impairments in a 
separate, and often completely disparate, measurement of hepatic insulin action (i.e. insulin 
signaling) signifies the presence of hepatic insulin resistance. This is not necessarily the case. 
The ‘gold standard’ for assessing hepatic insulin action is through the insulin clamp combined 
with isotopes of glucose to measure glucose fluxes. Other commonly used tests are not able to 
accurately assess hepatic insulin sensitivity. There are several other factors in addition to insulin 
resistance that can influence glucose tolerance. These include glucose effectiveness (i.e. the 
ability of glucose to suppress endogenous glucose production and stimulate glucose uptake) and 
insulin secretion and clearance. Thus it is plausible that impaired insulin action is offset by 
differences in glucose effectiveness. Measurements of arterial insulin concentration do not 
accurately reflect the insulin concentration in the portal vein; hence it is unknown whether 
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insulin concentrations at the liver are different and this could also contribute to the normal GTT 
results in the face of hepatic insulin resistance. Taken together this emphasizes the need to assess 
both glucose tolerance and insulin sensitivity as independent measurements when determining 
the metabolic phenotype of a novel rodent model.     
Focal adhesion kinase (FAK) is a key integrin-mediated regulator of insulin signaling 
(125,143-145). The phosphorylation of FAK at Tyr397 is associated with its activation. The 
studies conducted in Chapter III show that FAK Tyr397 phosphorylation is greatly reduced in the 
livers of HF fed wild-type mice compared to chow fed littermates. This is the first study to 
establish that FAK activation is decreased in whole liver homogenate with HF feeding.  This 
suggests that diminished FAK activation may contribute to decreased hepatic insulin action in 
HF fed wild-type mice. Future studies should be designed to test this hypothesis.  
Hepatic lipid content was decreased in both mouse models suggesting that integrins 
regulate hepatic lipid accumulation independent of specific pathways of insulin-signaling. The 
decrease in hepatic lipid accumulation in both mouse models was attributed to altered free fatty 
acid (FFA) metabolism. However, each model had its own unique features. The reduction in 
hepatic lipids in HF-fed integrin α1-null mice was attributed to a combination of decreased FFA 
availability upon insulin stimulation, decreased gene expression of the fatty acid transporter 
Cd36, and increased mitochondrial FFA utilization. In contrast, the observed decrease in lipid 
accumulation in mice with a hepatocyte-specific deletion of ILK was exclusively attributed to 
decreased circulating FFAs in the 5-h fasted and insulin clamped states. There was no difference 
in mitochondrial FFA oxidation observed in this model. It is important to note that the observed 
increase in mitochondrial FFA oxidation in integrin α1-null mice was present irrespective of diet. 
This suggests that the presence of integrin α1β1 decreases mitochondrial fatty acid supported 
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respiration. Additionally, in support of increased insulin action, mice with a hepatocyte-specific 
deletion of ILK on a HF diet exhibit increased complex I supported mitochondrial respiration. 
These studies establish for the first time a role for integrins in the regulation of mitochondrial 
function. 
Notably, expression of several genes implicated in de novo lipogenesis such as Srebp-1c, 
Fas and Acc1 were in fact increased despite decreased lipid accumulation. These are amongst the 
first studies to openly describe this observation. This suggests that a feedback mechanism exists 
to up-regulate lipogenic pathways when hepatic lipid stores are low and future studies could be 
conducted to monitor protein expression of key lipogenic proteins as well as rates of de novo 
lipogenesis using D2O to confirm this hypothesis. Moreover, this supports the broader view that 
lipid metabolites in the liver are shunted into neutral lipid droplets to protect against the 
deleterious effect of a HF diet. Collectively, the results from both mouse models reinforce the 
concept that circulating FFA concentrations contributes to hepatic lipid accumulation in the HF 
fed state. 
The studies outlined in the Dissertation are the beginning of an important new line of 
research that seeks to understand how integrins regulate hepatic insulin action in vivo. One goal 
of this work was to establish new therapeutic targets to ameliorate hepatic insulin action. The 
results in Chapter III show that integrin α1β1 promotes hepatic insulin action and lipid 
accumulation in the presence of over nutrition. This suggests that molecular activators of integrin 
α1β1 may improve hepatic insulin sensitivity but also increase lipid accumulation. In contrast, 
the results in Chapter IV show that the deletion of hepatic ILK improves hepatic insulin 
sensitivity and reduces lipid accumulation in high fat fed mice. This suggests that ILK inhibitors 
would be beneficial in the treatment of both hepatic insulin resistance and fatty liver disease.    
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In light of this, the role of integrins on insulin action and lipid metabolism within the 
hepatocyte warrants further investigation. It was noted earlier that the phenotype in the integrin 
α1-null mouse model may not be attributed to insulin action within the hepatocyte alone. At the 
time of the Dissertation studies, integrin α1 floxed mice did not exist, however integrin α1floxed 
mice have been recently generated by Dr. Ambra Pozzi. To address the contribution of 
hepatocyte integrin α1β1 to the described phenotype in Chapter III, further research is needed in 
mice with a hepatocyte-specific deletion of the integrin α1 subunit. 
Integrin β1 is the only known β integrin subunit expressed on the hepatocyte. In an early 
attempt to determine a role for hepatocyte integrin β1, integrin β1floxed mice (kindly provided 
by Dr. Roy Zent) were crossed with mice expressing Cre-recombinase under the albumin 
promoter. After much effort to generate mice with a hepatocyte-specific deletion of integrin β1, 
it was determined that this mouse model was embryonic lethal. This is supported in a recent 
study by Speicher et al. (207). The role of integrin β1 in mediating hepatic insulin action in vivo 
is critical for understanding the regulation of hepatic insulin action by integrins. To address this, 
future studies will be conducted in the laboratory using an inducible model of hepatocyte integrin 
β1 deletion.  
Considering that integrins α1β1 and α5β1 are the only known integrins expressed on the 
hepatocyte, it will also be important to establish whether integrin α5β1 also influences hepatic 
insulin action. Integrin α5β1 is a receptor for fibronectin. Preliminary studies from our laboratory 
suggest that fibronectin gene and protein expression is increased in the livers of HF-fed mice. 
This suggests that integrin α5β1 signaling may be increased in the diet-induced obese state and 
this contributes to decreased hepatic insulin action. The role of integrin α5β1 and fibronectin in 
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the pathogenesis of diet-induced hepatic insulin resistance will be examined in future studies in 
the laboratory.       
In conclusion, the studies described in the Dissertation establish for the first time a novel 
role for integrins in the regulation of hepatic insulin action and lipid accumulation in vivo. A 
strength of these studies is the emphasis on monitoring the in vivo pathways that regulate hepatic 
metabolism in a mouse model of metabolic disease. The regulation of hepatic insulin action in 
the diet-induced obese state is quite complex. Key metabolic pathways are not able to be 
measured accurately in tissue culture systems or in perfused livers. Many questions remain as to 
how metabolic disease develops and persists over time. The current work addresses the 
contribution of integrins to alterations in hepatic metabolism in the presence of nutritional 
overload. These studies emphasize the potential utility of molecular activators or inhibitors of 
integrin signaling as therapeutic targets to treat the underlying insulin resistance associated with 
Type 2 diabetes.    
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Chapter VI 
 
 
CONCLUSIONS AND IMPLICATIONS 
 
 
The data contained within this Dissertation are the first to describe a role for integrins in 
the regulation of hepatic insulin action and lipid accumulation in vivo. The results from these 
studies emphasize that integrins represent a novel therapeutic target to treat the underlying 
hepatic insulin resistance associated with Type 2 diabetes. The fundamental conclusions of this 
cumulative work include: integrin α1β1 protects against diet-induced hepatic insulin resistance 
while promoting lipid accumulation and a downstream integrin signaling molecule, integrin-
linked kinase, is a major contributor to hepatic insulin resistance and lipid accumulation in high 
fat fed mice.  
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